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Abstract

Introduction: Opioids are powerful pain killing medications that can be highly addictive and
can cause risk for overdose and even death (Michigan Prescription Drug and Opioid Task Force,
2015). Many primary care providers treat patients with acute and chronic pain, although it is
recognized that many receive inadequate training in pain management and feel unprepared in the
complexities of caring for these patients (Becker, Bair, Picchioni, Starrels, and Frank, 2018). To
treat these patients safely, provider education and adherence to guidelines put forward by these
initiatives is essential. Methods: An evidence-based prescribing toolkit was devised using
guidance from the literature and was presented to prescribers in two northern Michigan primary
care offices. The goal was to increase provider comfort level with opioid prescribing in primary
care, as well as to increase adherence to organizational policy, using several metrics. Discussion,
survey, and chart audits were used for evaluation. Results: Compliance with the Opioid Start
Talking Documentation and Medication Contract use increased post implementation (p < 0.05, ;
x2=3.95, p<0.05). Total morphine milliequivalents decreased from a mean of 42mmEQ/day to a
37mmEQ/day, which provided clinical relevance but was not statistically significant (S=757, p >
0.05). In addition, benzodiazepine co-prescription rates did not statistically differ pre- and postimplementation (p >0.05). Provider comfort level increased slightly but was not significant.
Conclusion: The evidence-based toolkit was effective at increasing organizational adherence but
not provider comfort level. Reduction of morphine milliequivalents and co-prescribing are
promising concepts that will likely improve over time.
Keywords: opioid, opioid guidelines, risk reduction, primary care
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Evidence-based Toolkit for Reduction of Overdose Risk in Primary Care Patients on Opioid
Therapy
Introduction and Background
Appriss Health (2018) indicates more than 7.8 million patients received over 103 million
opioid prescriptions over the course of a five-year data review in Michigan, resulting in over
5,000 patient deaths attributed to opioid prescriptions. According to the Michigan Prescription
Drug and Opioid Task Force (2015), the increased availability of prescription drugs along with
misconceptions around safety of prescribed medications has led to an exponential growth of
prescription drug users and mis-users. Further, drug overdose deaths have tripled since 1999,
with the majority being related to prescription drugs (Trust for America’s Health, 2015; as cited
in Snyder & Calley, 2015). The state of Michigan is ranked 7th in the nation for opioid
prescriptions and there was a 30% increase in overdose deaths from 2013 to 2015 (Appriss
Health, 2018).
This problem is significant because of considerations of the legitimate needs of patients
who require pain medication and the indistinct difference between safe and unsafe opioid
prescribing. Chronic pain remains a significant issue for millions of Americans and attempts to
reform opioid prescribing must have consideration for patients on existing opioid therapy and
those that have future needs for pain medication (Snyder & Calley, 2015). However, there must
be consideration of how to safely prescribe opioid pain medications through use of evidencebased guidelines that can help guide prescribing habits, regardless of whether the therapy is for
patients with acute or chronic pain conditions.
The 2015 State of the State Address by Michigan governor Rick Snyder called for a
comprehensive plan to address prescription drug and opioid abuse in Michigan (Snyder &
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Calley, 2015). Since this publishing, there have been varied attempts at reducing risk related to
opioid prescribing and additionally promoting use of tools in health care to reduce opioid
overdose rates. At the site for the project implementation, there were wide variations of practice
between providers in the prescribing and managing of pain with opioid therapies. With
development of an evidence-based toolkit, opioid prescribers have these tools at their fingertips
to safely and effectively prescribe for high risk patients. There also created the opportunity to
provide patient education that is recognized by the Centers for Disease Control and other top
agencies as a priority in this epidemic. The purpose of this paper is to describe an evidence-based
improvement in two rural northern Michigan primary care offices, within the realm of safe
opioid prescribing.
Evidence-Based Literature Review
A literature review is important and was conducted to identify familiarity with available
evidence on a topic. With a thorough review of the literature, it was determined how to aggregate
best evidence for translation and application in practice. The purpose of the literature review was
to synthesize the opioid prescribing best practice literature to generate a toolkit and guidelines
for implementation in primary care practices in rural northern Michigan.
Methods and PRISMA
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
guideline served as the framework for this review (Moher, Liberati, Tetzlaff, Altman, &
PRISMA Group, 2009). A comprehensive electronic search was conducted in the CINAHL and
PubMed databases and was limited to reviews in the English language during the period of 2008
to 2018. Keywords included opioid, opioid guidelines, risk reduction, and primary care. Similar
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search terms were used by application of Boolean operators (OR, AND) to both broaden the
search and include all relevant articles (see Appendix A).
For the purposes of the literature review, studies were identified if they pertained to
physicians. Any patient outcome data was included for patients 18 and older. The studies
centered on opioid prescribing and excluded other pain management strategies. Samples were
limited to applicability in primary care and other specialties were excluded. Studies pertaining to
palliative care, cancer and pediatrics/neonates were excluded.
For the intervention studies, an evidence-based opioid prescribing guideline had to be
implemented in a primary care setting. Outcome data related to the prescriber and/or patient had
to be generated to be included in the analysis, with the intended goal being identification of
whether implementation of the prescribing guideline was effective. Included were outcomes on
either the primary care provider’s adherence to the guideline or patient outcomes related to
application of the guideline in primary care practice. Also included was identification of the
effectiveness of education to promote the evidence-based guideline for prescribers in primary
care. A systematic review and quality initiative study were included to facilitate a well-rounded
approach to the literature review.
The search yielded 180 CINHAL reviews. One duplicate was found and eliminated from
the retrieved articles. Each article was screened using inclusion and exclusion criteria according
to PRISMA criteria (Moher et al., 2009). Review of titles and abstracts resulted in removal of
137 articles that did not meet the inclusion criteria. The remaining 43 articles were reviewed for
an in-depth examination of content, and all but six were excluded because they did not meet
inclusion criteria. The remaining six articles were included in this review (see Appendix B).
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Six CIHAHL and PubMed reviews met the inclusion criteria and are included. Three
studies were randomized controlled trials, one was a systematic review, one was quasiexperimental, and the final study included was a quality intervention. All studies included patient
outcome data related to quality and safety of opioid use following provider education
intervention or related to primary care provider outcomes. The quality intervention looked at
implementation of the Centers for Disease Control (CDC) 2016 guidelines for chronic pain
management and opioid prescribing.
All articles evaluated primary care prescribers who treat chronic pain with opioids. The
target was prescribers rather than patients, although some studies did put limitations around the
patient population being treated. For instance, all patients included in the prescriber’s panel
needed to be older than the age of 18 and needed to be undergoing opioid pain management for
non-cancer, non-palliative care pain. The focus was related to outcomes generated by changes in
prescriber habits and did not account for patient characteristics, such as duration of opioid pain
medication use, overdose risk, diagnoses specific criteria, specific age or gender or comorbidities.
All samples looked to identify implementation of a strategy to increase provider
knowledge and adherence for safer opioid prescribing techniques. Quanbeck et al. (2018) used a
variety of implementation strategies and a framework to put forward evidence prescribing
information to their providers. This study utilized audit and feedback, academic detailing and
external facilitation as methods to deliver the information to the prescriber. This study compares
four intervention clinics to four control clinics in a randomized matched pairs design (Quanbeck
et al., 2018). McCracken et al. (2012) utilized two different training experiences for comparison
to educate prescribers on opioid guidelines for chronic pain. One training looked to increase
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psychological flexibility and the other included training in practical knowledge and skills related
to pain management. Liebschutz et al. (2017) compared nurse care management, an electronic
registry, one-on-one academic detailing, and electronic decision tools for better adherence to
prescriber opioid prescribing.
Gaiennie and Dols (2018) utilized an information fair, training sessions, several quality
meetings and one-on-one information sessions to increase provider knowledge and adherence.
Finally, Von Korff et al. (2016) utilized statewide change education versus that of statewide and
group practice change education to impact provider prescribing knowledge.
There were various measures used in the samples reviewed. McCracken et al. (2012)
looked at provider prescribing practices, concerns about analgesic prescription, general wellbeing, the Acceptance and Action Questionnaire, the Mindful Attention Awareness Scale, and a
test of opioid knowledge. The providers completed the instruments, including surveys, tools, and
questionnaires and were again given these instruments pre-and post-intervention.
Several of the other samples looked at patient characteristics to account for the measures.
Liebschutz et al. (2017) utilized documentation of guideline concordant care using patient
provider agreement in the electronic health record (EHR), opioid refills and at least one urine
drug test in the corresponding twelve months’ post intervention. Quanbeck et al. (2018) utilized
several measures for outcome data, including overall opioid prescribing rates, average morphineequivalent daily dose for patients on long term therapy, rates of use of treatment agreements,
urine drug testing and opioid/benzodiazepine co-prescribing. These factors were evaluated at
both six and twelve months. Von Korff et al. (2016) utilized opioid days and total opioid
equivalency for pre-and post-measurements following intervention. Finally, Gaienne and Dols
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(2018) utilized number of opioid prescriptions and referral to pain management as outcome
measures.
Tournebize et al. (2015) used a systematic review of current evidence to identify whether
physicians in primary care are using safe approaches for prescribing opioids for chronic pain.
Each guideline was reviewed for risk associated with opioid analgesics, initial medical
evaluation, risk mitigation tools such as written treatment agreements, drug screening tests, dose
limits of opioid analgesics, periodic medical evaluation, opioid formulation and drug to drug
interactions.
Summary of Results and Evidence for Project
Five sources reported the outcome measures as improvement in provider knowledge and
adherence to guidelines and therefore positively influenced prescriber habits. Quanbeck et al.
(2018) identified cost savings with implementation of targeted education of over $7000. At a
year post implementation, there was a statistically significant reduction in morphine-equivalent
daily dose observed compared to the control. There was an increase in adherence to
recommended urine drug testing, use of treatment agreements, and opioid-benzodiazepine coprescribing rates (Quanbeck et al., 2018). McCracken et al. (2016) did not find a statistically
significant change in provider prescribing habits following training but did find that there was an
increase in intention to use prescribing methods as well as increase in provider well-being.
Liebschutz et al. (2017) identified a successful intervention related to reduction of total
opioid prescriptions and a 10% reduction in daily morphine-equivalent daily dosing. In one
sample, there was a 7% increase in patients referred to pain management and a 10% overall
reduction in number of opioid prescriptions (Gaiennie and Dols, 2018). In a systematic review, it
was identified that over 70% of physicians do adhere to opioid risk reduction strategies. There
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are opportunities regarding more regular assessment and re-assessment of pain scores as well as
with utilization of screening. Further, there is an opportunity to reduce risk of prescribing
fentanyl patches to opioid naive patients (Tournebize et al., 2015).
All articles examined in the literature review provide evidence for the proposed project.
The five articles concisely demonstrate the abilities for the DNP student to apply principles of
the literature review to the project. All articles provided relevance for evidence to be used to
guide the implementation of this project.
Organizational Assessment
An organizational assessment (OA) is a process for obtaining valid and useful
information on the factors that affect the performance, culture, capacity and motivation of a
specific organization (Lusthaus, Adrien, Anderson, Carden & Montalvan, 2002). Understanding
baseline performance before enacting change creates the ability to recognize the patterns,
linkages and philosophies of the organization for the change to be successful.
Burke and Litwin Model
The Causal Model of Organization Performance and Change, otherwise known as the
Burke & Litwin Model, uses several key principles to suggest how an organization may be
affected by a change (see Appendix C). According to Burke and Litwin (1992), change must be
well strategized to fit an organization before it can be successful. Change comes with a
significant impact on many factors that influence an organization, including strategy, leadership
and culture (Burke and Litwin, 1992). The model is an important initial step conducted in the
DNP student project.
Burke and Litwin first discus transformational factors, which are initially examined with
relevance to the DNP project. The transformational dynamics of the model are defined as the
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areas of an organization “in which alteration is likely caused by interaction with environmental
forces (both within and without) and will require entirely new behavior sets from organizational
members” (Burke and Litwin, 1992, p. 529). This encompasses the external environment,
organizational culture, mission and strategy, individual and organizational performance and
leadership (Burke and Litwin, 1992).
Burke and Litwin (1992) indicate any outside condition or situation that influences the
performance of an organization is referred to in the model as the external environment. This is
how things like governmental circumstances or political influences are endured by an
organization. While there are many external factors that are relevant in healthcare, the most
pivotal changes have recently been deployed by the state of Michigan in a legislative overhaul of
opioid prescribing. Appriss Health (2018) did a statewide opioid assessment to understand the
current state in Michigan regarding overdose data. The need for increased awareness and
attention to opioid prescribing led to several pivotal legislations, including mandated use of
prescription monitoring systems and limitations on the number of days written for acute pain
(Cavitt, 2017). There are also local endeavors to combat the opioid crisis, including community
efforts to increase awareness and knowledge of addiction, treatment for opioid use disorder and
disposal of medications in a safe and effective way.
Culture is defined by Burke and Litwin (1992) as the collection of overt rules and values
that guide organizational behavior. This is specific to the values and customs of the organization
and provides a sense of meaning to the members of the organization. These statements provide
meaning to be a member within the organization and include the concepts of “own it, patient
impact, resources and relationships, high performance, one team, and financial health” (XXI,
2018). Additionally, the larger organization has a set of values that are shared by all the
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organization, and these include the values of integrity, respect, teamwork, excellence,
compassion and accountability (XXII, 2018).
The culture of the primary care practice is also in support of the lived values of the
organization, both on a macro and micro level. The practice has adopted a primary care process
that includes a concept called “Kaizen Culture” in which the employees are able to bring forth
change from all levels. The goal is engagement from all staff and encouragement for change by
communication in a way that reduces confusion and allows for collaboration on behalf of the
practice.
According to Burke and Litwin (1992), leadership encompasses the overall
organizational direction and serves as the role model for all employees. Not only is leadership
evaluated as necessary and valued commodity, but it also includes the evaluation and perceptions
of followers when it comes to executive practices and values (Burke and Litwin, 1992). The
practice has a chain of command system that serves as a way of problem solving and raising
concerns. The larger organization holds office to a president, followed by an organizational
structure that leads down to the micro level. The practice has a director, manager and newly
appointed supervisor. All three of these roles are shared among other primary care offices in the
area. These leaders strive to embody the values of the organization and provide timely and
appropriate decision making and problem solving that helps the practice with day to day
operations.
Mission and strategy are defined as what the organization’s top management believes is
the forward-thinking approach that is central to the organization’s success, including how the
organization intends to achieve purpose over time (Burke and Litwin, 1992). As indicated
previously, the primary care practice functions under an umbrella of leadership that includes a
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larger organization, whose mission is to improve the health of the communities that are served
(XXIII, 2018). There are several key initiatives that are aimed at this goal, including a recent
large-scale change of the EHR and overall strategic goal to improve the organization’s approach
to patient care, with a “one patient story” approach.
The outcome or result as an indicator of effort and achievement allows for understanding
of the individual and organizational performance of an organization (Burke and Litwin, 1992).
This includes productivity, customer satisfaction, profits and quality of an organization. The
primary care practice strives to identify and utilize these factors and utilizes a team of specialists
that are devoted to using data productively.
Next, Burke and Litwin (1992) identify transactional factors, which are combined with
transformational factors that allow for recognition of the way an organization thinks about a
change. According to Burke and Litwin (1992), transactional factors are defined as the primary
way of alteration that affects people and groups. Included in transactional factors are
management practices, policies and procedures, structure, work unit climate, tasks and individual
skills, motivation, individual needs and values and individual and organizational performance
(Burke and Litwin, 1992). Each of these factors is described in greater detail in the following
paragraphs.
Burke and Litwin (1992) identify management practices as the way leaders use human
and material resources to carry out to the organization’s strategy. This is carried out at the
practice using the Kaizen culture that was introduced earlier. There is a process where employees
are able to put forward a problem using a process improvement method of ‘golden tickets’ which
can be a way to encourage staff to identify an innovative approach to tasks and projects to
improve the healthcare delivery at the practice. Additionally, there is a concept called the clinical
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practice model, or CPM, that allows for employee led change. There are monthly meetings
where staff lead a group of fellow peers, with oversight by the supervisor or manager, and
changes are promoted and enacted. The influences of peers on change can be an important
structure for staff to feel comfortable.
The structure is the arrangement of people into specific areas to carry out the functions
and responsibilities of an organization, including decision making authority, communication and
relationships (Burke and Litwin, 1992). Good communication by leadership to employees is the
key to assure effective implementation of strategies to align with the organization’s mission.
While the providers are ultimately responsible for the care of the patient regarding opioid
prescribing and pain management, the medical assistant and registered nurse communicate and
assess patients on a routine basis. Therefore, their understanding of the legislation around the
pain management initiatives is important, as well as their closed loop communication with the
provider.
Standardized policies are seen by Burke and Litwin (1992) as the mechanisms that
facilitate the work in the organization and controls systems such as performance appraisal, goal
and budget development and human resource allocation. There are many different policies and
procedures that guide pain management at the organization. These are the driving force for how
staff care for patients who present with pain complaints. The policies and procedures are
informed by the accrediting body, The Joint Commission, as well as driven by organizational
management to align with the key strategies of the organization.
A collective set of current impressions, expectations and feelings that staff members have
that affect their relationships with one another, their leader and other practices is known as
climate (Burke and Litwin, 1992). The climate within the primary care office is positive. There
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are ways to promote change and for employees to have their voices heard. The CPM group, as
mentioned previously is a way for culture to be promoted through staff-led change.
Motivation is thought to be aroused by behavioral tendencies with movement toward
goals, taking needed action and persistence until satisfaction is attained (Burke and Litwin,
1992). Burke and Litwin (1992) indicate there are many attributes rolled into this phenomenon,
including the energy that is generated by the sum of achievement, power, affection, discovery
and other human motives. This is the driving force for employees in their work environment and
urges their ability or inability to get things done in the work place. The staff are goal oriented
and motivated by their daily work. This is evidenced by their vigor and attention to the recent
opioid legislation change and adoption of standard work.
Required behaviors for certain tasks, including specific skills and knowledge required of
people is described by Burke and Litwin as the skills necessary to possess to accomplish the
work for which a person has been assigned (1992). Staff members take their roles very
seriously, and practice with the best of their ability to attain the values of the organization. Some
of the staff are licensed for their role, including providers and registered nurses. Medical
assistants are certified, non-licensed personnel but must adhere to the job description and
complete various competencies to demonstrate abilities pertinent to the functions of the role.
Psychological factors that provide desire and worth is known by Burke and Litwin as
individual needs and values (1992). This creates job satisfaction and generates the work-related
needs and values of an organization. The need to understand differences among people’s needs
and values is important, and recognition is a vital part of what makes the organization successful
in recruitment and retention.
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Burke and Litwin (1992) identify individual and organizational performance as the
outcome or result at the organizational level. This is a way to identify productivity, customer
satisfaction, profit and quality.
Strengths, Weaknesses, Opportunities and Threats (SWOT)
The identification of the strengths, weaknesses, opportunities and threats (SWOT)
provides a platform for the project planning (Moran, Burson and Conrad, 2017). The purpose of
a SWOT analysis is to identify key areas in contingency planning, help to identify trigger points
and provide data for a gap analysis. According to Moran et al. (2017), the SWOT analysis looks
at both the internal and external attributes and threats to the phenomenon (see Appendix D).
The site for implementation had many strengths. The primary strength is that there is
engagement at the leadership level from the supervisor, manager, director and up through the
chain of command. The onsite manager and supervisor have an open-door policy and allow time
for staff to bring questions and concerns. There is low provider and staff turnover in the office,
which allows for consistent practice over time. There are also consistent provider/medical
assistant relationships. There are also golden tickets, clinical practice councils and a high
attendance monthly staff meeting.
Rural health is plagued by long distances for patients to travel, as well as fewer providers
per capita than in urban communities (Rural Health Information Hub, 2018). Unfortunately, this
is the case in the counties in and immediately surrounding the clinic. Each provider has a high
panel load, which creates challenges for patients to access their primary care provider.
Appointment times are short, producing additional challenges to cover the items a patient may
wish or need to discuss. Additionally, there are many other mandatory screening tools used due
to various other projects and initiatives aimed at quality and safety, which takes time during the
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visit. Finally, there have been system wide changes with the EHR, so there has been a myriad of
change in recent times. This can lead to burnout staff and providers.
Consumer demographics in the area make the opportunity to impact health on a big scale
more important. The counties surrounding the clinic have high opioid prescribing rates and
statistics indicate at least one patient per month presents to the area emergency departments for
overdose (XXIV). There have been recent state policy changes in the state of Michigan regarding
opioid prescribing. To match this, the system is producing a policy that will provide guidance
and oversite for prescribing and will be adopted based on the recent state and national legislation.
Finally, the clinics are part of a larger organization that help to move initiatives along and
provide a good climate for change.
Pain management has always been a topic of discussion with patient satisfaction. This
provides a threat, given patient satisfaction scores for pain management have an opportunity to
decline with new changes in prescribing. Patients who are on long-term regimens for pain
management are less likely to feel empowerment with changes to their dosing and care plan if it
has been “working for them.” As mentioned previously, there are legitimate pain concerns to
consider for patients presenting with painful conditions. According to the Rural Health
Information Hub (2018), there are limitations in health literacy in rural communities, which is
likely evident within the surrounding counties and during the clinical rotations at the site by the
DNP student.
Stakeholders
There is significance in inclusion of key stakeholders for any change, as the stakeholders
are those who are most affected by the change. Key attributes of successful interventions are the
perception of key stakeholders, including how well the project is presented (Greenhalgh, Robert,
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Macfarlane, Bate, Kyriakidou, 2004). This was investigated prior to enacting the project. A letter
of support was provided for the DNP student to enact the project at the site prior to the student
attending the site (see Appendix E).
Key stakeholders for this project included the providers prescribing and assessing
patients in primary care, the medical assistants and registered nurses who interact with the
patients both in the office and on the phone, as well as office leadership (supervisor, manager,
director). Additionally, guidance from the pain management clinical nurse specialist, and key
mentors for the project serve as stakeholders. Patients also serve as a stakeholder in the project.
Finally, there are several key mentors guiding this work, including several physicians, professors
and additional site resources.
Phenomenon Conceptual Models
Chronic Care Model
A phenomenon conceptual model served as a guide for the project. The Chronic Care
Model is one that can be applied to the project, as it is an organizational approach to caring for
people with chronic disease in the primary care setting (Improving Chronic Illness Care, 2018).
According to Moore et al. (2016), successful organizational improvement processes depend on
application of metrics that are reliable as a goal to set targets and to monitor progress for the
intervention. It has been demonstrated that improvement in the management of guidelines for
pain can have better adherence when guided by an implementation model (Dorflinger, Moore,
Goulet, Becker, Heapy, Sellinger & Kerns, 2014; Moore et al., 2016;). This model applies
because of the need for patient preference and needs, improvement in available clinical
information for providers and developing a safe healthcare culture both inside the facility as well
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as in the community (Levenson, 2017). There are six key aspects of this model, better explained
below (see Appendix F).
Community resources. The goal of the community resources aspect of the Chronic Care
Model is to mobilize community resources to keep chronically ill patients supported, involved
and active (Improving Chronic Illness Care, 2018). There is encouragement for patients to
participate in community programs, form partnerships with organizations to support and develop
interventions that fill gaps in needed services and advocate for policies that improve patient care.
The healthcare system. The goal of the healthcare system concept within the Chronic
Care Model is to create a process that provides safe, high quality care. The healthcare system
works to support improvement at all levels of the organization and promote effective
improvement strategies aimed at comprehensives system change (Improving Chronic Illness
Care, 2018). The healthcare system encourages incentives based on quality of care and identifies
and engages agreements to facilitate care coordination within and across the organization
(Improving Chronic Illness Care, 2018).
Patient self-management. Patient engagement is a large part of the Chronic Care Model
as is important for prevention and detection, management of the disease by the provider and selfmanagement by the patient (Levenson, 2017). There is importance in this aspect of the model to
empower and prepare patients to manage their health care delivery, set goals, identify barriers
and challenges and to monitor their own conditions. There are support strategies involving the
provider, that include assessment, goal setting with the patient, action planning, problem solving
and follow up (Improving Chronic Illness Care, 2018).
Delivery system design. According to Improving Chronic Illness Care (2018), the
decision support initiative within the Chronic Care Model is to assure effective, efficient care
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and self-management support. This helps to define roles and distribute tasks among team
members, use planned interactions to support evidence-based care, ensure regular follow-up by
the healthcare team and give care to patients that is both holistic and culturally competent
(Improving Chronic Illness Care, 2018). The site for implementation reports through a structure
of governance for delivery system design and are supported in this way.
Decision support. To promote care consistent with data and patient preferences,
clinicians must have convenient access to the latest, evidence-based guidelines for care of
patients with chronic pain. There should be continued educational outreach to prescribers that
reinforces utilization of these standards (Improving Chronic Illness Care, 2018). The goal is to
embed evidence-based guidelines into daily clinical practice, share guidelines and information
with patients and encourage their participation, and integrate specialist expertise to educate
prescribers effectively.
Clinical information. Finally, the concept of clinical information systems is to organize
data to facilitate efficient and effective care. Healthcare systems harness technology to provide
clinicians with information they need at the point of care, to give the most necessary and
important information possible. These allows for evidence-based guidelines to be embedded into
daily clinical practice, with timely reminders, identification of specific populations of patients for
proactive care, facilitation of individual care planning, and monitoring the performance of a care
team (Improving Chronic Illness Care, 2018).
Kotter’s Eight Step Change Model for Leading Change
John Kotter (1996) developed an 8-step Model of Change, which was created utilizing
research of over 100 organizations going through organizational change (Kotter, 2018). The
steps in the model allow for clearly defined steps to managing large scale change in the
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organization and assist with the transition through varied points of challenge that come with
change management. The eight steps to change are outlined in the following section and applied
to the DNP project (see Appendix G).
The goal of the first step in Kotter’s model is to help others see the need for change,
through creation of a sense of urgency, which can be a powerful tool for change management
(Kotter, 1996). This is done through involvement and support of the key stakeholders and
customers on the issue of the change, as well as in honest dialogue and discussion that makes
people think about the prevalence of the issue, as well as convincing argument to why the change
is necessary. Finally, this step can be accomplished by examining the potential threats that may
come up through implementation of change (Management Study Guide, 2018).
The second step in Kotter’s 8-Step Model includes identification of effective people for
the proposed change, who can help guide, coordinate and communicate change activities
(Management Study Guide, 2018). Kotter identifies the third step as identification of how the
future will be different from the past and how the change initiative may make the future a reality
through interventions linked to the vision. Communication is a key during processes creating
change. It is critical that the vision is powerfully and convincingly managed. This vision should
connect with all crucial aspects like performance, training and the project steps themselves
(Kotter, 1996).
Removal of barriers is an essential part of processes enacting large scale change.
Inefficient processes and hierarchies can provide barriers to projects and removing these can
assist with forward motion of the project (Kotter, 1996). The DNP student worked to understand
and identify barriers to assist in barrier removal.
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According to Kotter (1996), wins should be recognized, collected and communicated
early and often both to track progress and to energize participants through the stages of the
project. Short-term wins along the way should be numerous and attempt to create forward
traction in the provider buy in for the work. Following the first success, Kotter suggests
increasing the pace to press harder (1996). This will increase credibility to improve systems,
structures and policies. Until the vision is reality, change after change should be accelerated. In
the final stage, instituting change, Kotter states there should be articulation between the new
behaviors and organizational success, ensuring there are strong enough connections for the new
behaviors to push out old habits (2016). This is the final state of Kotter’s model and accounts for
the learned behaviors that become new practice.
Clinical Practice Question
At the organization, there were wide variation of practices between providers in the
prescribing and managing of opioid therapies. The toolkit approach has been taken by the
Centers for Disease Control and Prevention for other topics related to pain control in a way to
help reduce rates of overdose. Currently, there are many toolkits published that provide access to
relevant prescribing information for providers but there is not a toolkit available that bundles
relevant evidence-based practices to all essential elements of the proposed project in a consistent,
concise way that can be of benefit specific to primary care providers. The goal of this evidencebased opioid prescribing implementation was to provide information to prescribers in primary
care to reduce risk of overdose in patients on opioid therapy. Toolkits have been used to assist in
change management in a variety of ways and provide guidance and evidence to team members
(Clancy, 2013). The toolkit includes the expected actions of each of the team members,
establishes role accountability, documentation and monitoring. Each of these factors supports
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team effectiveness and use of evidence-based guidelines to help deliver care. Accordingly, an
evidence-based project to answer the following practice question is proposed: Does
implementation of opioid guidelines increase provider awareness of opioid prescribing best
practice, reduce risk of unintentional overdose and increase adherence to organizational policy?
Project Plan
Purpose of Project and Objectives
The overarching goal of the project was to assist primary care providers in their care of
patients on opioid therapy, for acute or chronic pain management. This project aimed to assist
with provider education of the new Michigan Legislation changes regarding opioid prescribing,
worked to help reduce risk of overdose in high risk patients and had a goal of assisting in
identification of ideal candidates for naloxone prescription. It also looked to delineate expected
prescribing practices and processes supported by the clinical team member roles and
documentation support.
The toolkit was aimed at allowing providers to have a concise set of standards that
follows both national and Michigan laws and adheres to the policies set forth by the organization.
The project was one that was deeply desired by the organization and will provide value in
aligning with their key objectives of “healing the whole person.” The toolkit contents were
driven by a new guideline put forward by the organization as well as evidence outlined by the
several different national prescribing guidelines that are highly recognized by the organization.
The goal objectives for measure included increases in provider awareness and comfort
with adherence to opioid laws and policies, increased adherence to organizational policy
(utilization of contracts and Michigan Start Talking Document), reductions in total morphine
milliequivalents in patients on opioids, higher rates of naloxone co-prescription, and reduction in
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patients with commitment benzodiazepine and opioid prescriptions and finally. As a separate tier
to the work, an informatics initiative was requested for easier identification of high-risk patients
and ease of ordering naloxone, when suggested. Each of the objectives were measured and
assessed pre- and post-implementation of the toolkit.
Design for the Evidence-based Initiative
The design for this evidence-based initiative was a quality improvement project and
translation of evidence into practice. A quality improvement project consists of a systematic
action that leads to measureable improvement in health care services for a targeted group (U.S.
Department of Health and Human Services Health Resources and Services Administration
[HRSA], 2011). The Institute of Medicine, a recognized leader of improving the nation’s
healthcare, defines quality in health care as “correlation between the level of improved health
services and the desired health outcomes of individuals and populations” (HRSA, 2011, p. 1).
Setting and Participants
The setting for this project was two small primary care locations in rural northern
Michigan. The services provided at the primary care offices includes health and wellness visits,
prevention, sick visits and chronic care for patients across the continuum, from birth to geriatrics.
These clinics provide care in the Northern counties of Michigan, connected to a larger
organization and strives to create parity in healthcare access for rural county populations. The
highest volume diagnoses in the primary care clinics are diabetes and hypertension. Joint/limb
pain and neck/back pain are within the top four diagnoses. Between both clinics, there are eight
providers, including three physicians, two nurse practitioners and three physician assistants.
Additionally, there are ten medical assistants, one triage phone nurse and the number of patient
visits per year is approximately 28,000. The DNP student sought and obtained administrative
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approval to conduct the project at these sites, including support from office director, manager
and the medical director for both sites. The executive approval came from the chief nurse of the
overseeing affiliated hospital and was supported by administration at the site.
The target population included provider prescribers at the site, as well as medical
assistants and registered nurses who provide care to patients. While the toolkit is aimed at
assisting with habits of opioid prescribers, it was also utilized by front line staff who interact
with patients and who were expected to also adhere to state law and office policy related to
documentation. Front desk and clerical staff were excluded from the initiative. Only clinical staff
were included in the intervention.
Ethics and Protection of Human Subjects
An application for review and approval for the project was submitted to the XXX
Institutional Review Board (IRB) as well as the Grand Valley State University (GVSU) IRB (see
Appendices H and I). The purpose and scope of this project was limited to evidence-based
practice improvement or quality improvement. No intended physical, social, psychological,
legal, or economic threats to patients were associated with this project. As such, it was
anticipated that the impact of the project will pose minimal or no risk to participants. All
members of the team have completed human subjects’ protection training via the Collaborative
Institute Training Initiative and their interactions with patients will be guided accordingly. The
DNP student has also signed all forms required by the site to maintain confidentiality and to
uphold requirements requested by the site.
The DNP student recognized the need for additional data permissions that were sought
and obtained during the project. The data review was challenging in terms of discrete data details
for reports to pull reports desired by the organization and student for analysis. Therefore, the
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DNP student sent an email to the site’s IRB to obtain additional data permissions for the project
(see Appendix J). This was granted and discussed with the site mentor, GVSU mentor and the
quality lead for the project site.
Data Collection Procedures and Management
The DNP Student did the primary data collection for the project and utilized assistance
from a data analyst at the site. The data elements collected were primarily associated with the
project variables and were carefully selected to provide relevance to the project (see Appendix
K). While the goal of data analysis was to be completed prior to the rollout of the toolkit,
additional IRB permissions were needed and delayed access to data. Therefore, the data was
collected from the EHR following the implementation of the toolkit, with retrospective review.
Data was again collected at the cessation of one month’s time, post implementation. The sample
size of data included a total of 61 patients for review for the retrospective review and a total of
20 after a month’s time. The site provided very explicit guidelines regarding use of data and
therefore, all EHR data utilized the processes enacted by the site for both privacy and
confidentiality.
A data collection tool utilized to understand provider prescribing awareness and comfort
level pre- and post intervention. This data was gathered prior to enacting the toolkit and was
provided after implementation. The survey used a Likert style format, with ratings from 1
(strongly disagree) to 5 (strongly agree). See a sample in Appendix L.
Guided by evidence from the literature and site stakeholders and experts, the survey tool
was created utilizing questions geared to reduce time spent completing the survey while still
capturing the most critical data elements. There was no need to obtain copyright for this uniquely
created tool. The goal was to identify whether providers felt comfortable about opioid
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prescribing and had awareness of the state and legislative changes in opioid prescribing practice.
This was assessed pre-implementation and post-implementation.
The organization had very specific data collection and management policies, and it was
the student’s responsibility to follow procedures explicitly. The data was collected by the data
analyst for the site. This was completed by running a report for patients from the EHR. Once the
report was generated, the data analyst placed this information on a secure, password secured m:
drive that will be also secured using password encryption. The data was then evaluated and
organized by the student.
The data variables that were relevant to the project were reviewed in the EHR, deidentified by the DNP student and provided to the statistician for review. There was no ability to
identify any patients or providers. The only person with access to the data for the project were
the data analyst and the DNP student. All other parties, including the site mentor and faculty did
not have accessibility by any means. Following the cessation of the project, all data was
destroyed.
Steps for Implementation
The following steps outline the DNP student’s activities used to complete this quality
improvement work (see Appendix M for timeline).
1). Create Urgency
•   Completed the literature review and organizational assessment to understand current state
of the problem and the organization’s unique needs.
•   Presented the topic across various forums to gain support and traction about the need for
the work.
2. Formed a coalition prior to implementation.
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•   Met with the medical director to discuss the project’s anticipated direction and evidence
for the project. The medical director is a local addiction specialist and is assisting in
providing the foundational approach for the go live.
•   Met with the site’s executive leadership and guiding members, including the pain
management CNS, site director and director of operations to establish the content for the
toolkit.
•   Attended clinical practice steering meetings
•   Cultivation of relationships with provider and medical assistant staff members.
3). Created a vision for change with creation of the toolkit, using the following as a guide.
•   Evidence-based guidelines
•   Organizational policy
•   Requests by site leadership and provider staff
4). Communication of the vision through education and information around the toolkit to all
involved.
•   Presentations
•   Emails
•   1:1 discussion and education sessions
o   This included education around the evidence from the literature and the toolkit
itself.
5). Empowered action: go-live with the evidence-based toolkit.
•   Provided weekly rounding times for updates and discussion
•   Provided additional support and tools as needed.
6). Create quick wins
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•   Creation and embedding a best practice advisory for morphine mill-equivalency within
the EHR. This required several presentations by the DNP student to the ambulatory
informatics steering committee and required executive approval at this level.
•   Several meetings took place to determine and understand the existing functionality of the
EHR and the future upgrade regarding the informatics request.
7). Build on the change
•   Weekly feedback to providers and staff
•   Report provided on progress
•   Discussion of key points and reinforcement of concepts.
8). Make it Stick
•   Delivery of final report to leadership, prescribers and staff.
•   Presented sustainability plan and next steps
Process Mapping/Timeline
Process mapping is a quality improvement tool commonly used to better understand the
health care process within the practice system (HRSA, 2011). This provided a visual diagram of
the sequence of events that result in an outcome. This was particularly helpful as the DNP
student worked to objectively determine the timeline and outcomes for the project. Further, this
was also used as a guide for the intervention. In primary care, there are many different
interactions with the patient for opioid prescribing and the process map helps to clarify who has
what role in the process. According to the HRSA (2011), this is a helpful tool to assist in creating
change for quality improvement projects.
Project Evaluation and Measures
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According to the HRSA (2011), data is the cornerstone of a quality improvement project.
It is important to understand how well the current system supports the provider’s workflow
regarding patients who may be on opioid therapies. The goal of data collection was to separate
what is thought to be happening with what is known based on data, as well as to establish a
baseline for practice. It also reduces placement of ineffective solutions or those that do not
address a tangible problem. Data collection helps with monitoring change and ensuring
improvements were effective and sustained. Improvements can be identified using data when
compared to baseline (HRSA, 2011). Data collection was through surveys and chart review in
the EHR.
Each objective must be measurable as defined by the HRSA (2011). To assist with
implementation, a pre-knowledge survey for opioid proscribing was developed and given to all
available prescribers. The DNP student also attended goal setting education about opioids and
prescribing, an initiative that the health system implemented in December 2018. This gathering
of system-stakeholders and prescribers was strongly encouraged for providers to attend and
provided additional direction for the project.
The toolkit was developed using an evidence-based approach and included information
guided by best practice and literature. The organization had several resources that were most
utilized when evidence-based information is desired, including the CDC references, UpToDate,
the Lazarus Project and others. This was paired with the organization’s guideline put in place to
assist with opioid prescribing (see Appendix O). These resources proved to be the primary
source of collection for information included in the toolkit. Several checklists were created to
assist in provider, RN, and MA staff in adherence to the guidelines by the organization and state
of Michigan for opioid prescribing and this was included in the toolkit (see Appendix S).

ARIS FINAL DEFENSE

34

Additional resources in the toolkit provided increased awareness of responsibilities, expected
documentation in the EHR, expected communication to patients, criteria for referrals to other
providers, psychosocial support resources, screening recommendations and other clinical care
interventions. Screenshots were provided for screening tools (see Appendix P). Finally, naloxone
resources were provided with the CDC patient education materials (see Appendix Q).
Analysis Plan
The data was analyzed by the DNP student. The pre-implementation data was exploratory
data and provided an understanding of current state practices at the site. Ultimately, this data was
not readily available until after the proper permissions were granted through the IRB and was
retrieved and reviewed after implementation of the project. Once available, the student compiled
the chart review and presented results to key stakeholders.
The post-implementation data was again gathered by the student. This was then analyzed
using suggested statistical methods for the data presented to the statistician. The DNP student
collaborated with the GVSU statistician to determine the appropriate statistical methods and
level of significance. Output for each of the measures was included and given to the student. This
data was then displayed using graphs, tables and charts (see Appendices, as outlined in the
results section of the paper).
Resources and Budget
The budget was important part of the DNP student project because of the need to enact a
project that is sustainable and valued by the organization. Most of the costs for the project were
donated by the DNP student, who served as the data collector and the project manager for the
project (see Appendix Q). The time creating the educational plan and toolkit was calculated, and
this included primarily the review of the literature and evidence-based recommendations, pulling
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together the organization’s desire opioid recommendations, printing materials and putting
together the binders for presentation. The educational initiatives were varied, including email,
and attendance with the providers one on one. There were several times that the DNP student
needed to be at the project site for support around the implementation, totaling around six hours.
The hours associated with the DNP student’s time includes that at an RN rate (approximately
$30 per hour).
The DNP student also donated printing and one binder for each provider to have in their
own office for the intervention. Additionally, there was time required for the data analyst to pull
and supply data to the DNP student for the project, as well as time spent by the statistician
placing the information into a workable format. Average salaries were calculated using data from
US Bureau of Labor Statistics in 2018. All monies are described in a table format in Appendix R.
According to Mack (2018), the overdose rate in Mecosta, Osceola and Lake counties was
10 patients in 2016. White et al. published an article in 2005 that indicated that for each overdose
death, there were 33 related emergency department visits and 11 substance abuse treatment
related admissions (Journal of Managed Care 2005). Additional sources indicate this information
is still relevant. Therefore, most the revenue generation is targeting the average of ten overdose
deaths and preventing those emergency department and substance abuse inpatient admissions.
Results
The evidence-based intervention took place in rural northern Michigan at two primary
care sites. The current practices of opioid prescribing were assessed. The goal of the analysis was
the determine how the evidence-based toolkit could be used to drive practice and to identify the
variability among prescribing habits between various providers at the two sites. To do this, a
report from the data analyst was generated following approval from the site’s Institutional
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Review Board (IRB). This report contained data over a year’s period, calendar year 2018. The
report included all opioid prescriptions generated out of each practice during that timeframe.
Both short and long acting opioid medications were included in this report. The DNP student
then did complete chart reviews to isolate the discrete data points to be reviewed for the project.
During this analysis, it was assumed that the patient picked up their prescription and was taking
the medication as prescribed.
Over the calendar year 2019, between the two practices there were 428 total opioid
prescriptions generated. Each unique prescription was associated with a patient, although some
of the data reflected more than one prescription to the same patient. Duplicates were removed,
and methods were used to isolate the charts to be examined. These are discussed in more detail
further in the results section. A manual EHR review of 26 charts (site A) and 39 charts (site B)
were assessed at each site. Variables collected were age, gender, short acting opioid, long acting
opioid, total daily morphine milliequivalents (mmEQ) prescribed, compliance with urine drug
screen, presence of the Michigan Start Talking document and pain management contract,
whether naloxone had been prescribed, presence or absence of a benzodiazepine at the time of
opioid prescription, existing pain management referral, and whether there was a diagnosis related
to opioid use or overdose. Finally, it was assessed whether there was use of screening tools to
assist in assessment of patient function and goals. The data was reviewed to assist in description
of the population of patients at the practices who were receiving opioid prescriptions.
Pre/Post Implementation Prescribing Characteristics
Site A: Pre-implementation. The data analyst was able to pull an entire year’s worth of
data, including duplicates. This entire data set was also analyzed for use patterns for preimplementation data. At site A, the average age of patients receiving opioids was 56 years old
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and there were ten female patients and twelve male patients. at site A, there were 48 total
prescriptions for opioids in calendar year 2018. Of these, the primary medication prescribed was
hydrocodone-acetaminophen 5-325mg, with a total of 32 prescriptions written. Hydrocodoneacetaminophen 10mg-325mg was prescribed eleven times, while hydrocodone-acetaminophen
7.5mg-325 and hydrocodone polistirex-chlorpheniramine was prescribed a total of three times.
Of these 48 prescriptions, there was a total of 22 unique patients, with four patients receiving
more than one prescription. These duplicates were removed for the analysis, leaving a total of 22
patient charts reviewed at site A.
Of these unique patients, fifteen had a prescription for hydrocodone-acetaminophen 5325mg, three patients had a prescription written for hydrocodone-acetaminophen 10-325mg, 2
patients had been prescribed hydrocodone-acetaminophen 7.5-325mg, and two patients were
prescribed the hydrocodone polistirex-chlorpheniramine. As hydrocodone-acetaminophen 5, 7.5
and 10mg doses are noted to be short acting medications, this was the primary type of
medication prescribed, while hydrocodone polistirex chlorphenirmaine as the only long acting
medication prescribed at site A. There were no instances where patients had both a long and
short acting opioid prescribed.
Site A: Post-implementation. Post implementation at site A, there were a total of six
prescriptions written from February 18-March 18, 2019. The average age of patients receiving
opioids in the calendar month was 62. There were four male patients and two female patients.
The primary medication prescribed was hydrocodone-acetaminophen 5-325mg, with a total of 4
prescriptions written. There was one prescription for a fentanyl patch (24mcg/24 hours) and one
prescription written for hydrocodone-acetaminophen 7.5-325mg. These were all unique patients,
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with no duplicates. There were no instances where patients had both a long and short acting
opioid prescribed.
Site B: Pre-implementation. At site B, a total of 379 prescriptions were written for
opioids in calendar year 2018. Of these, there were 142 prescriptions for hydrocodoneacetaminophen 10-325mg, 84 prescriptions for hydrocodone-acetaminophen 5-325mg, and 34
for hydrocodone-acetaminophen 7.5-325mg. Additionally, there were 31 prescriptions for
methadone 10mg, 19 prescriptions for methadone 5mg and 17 prescriptions for morphine 60mg
extended release. Other medications ordered included various formulations of both short and
long acting oxycodone, oxycodone-acetaminophen, and morphine. There were two instances of
fentanyl patch prescriptions and one prescription for codeine.
As there were many opioid prescriptions written at site B, a review of the first patient
and then every 10th patient listed was performed to ensure randomization, and a total number of
39 patients were reviewed. There were 24 female patients and fifteen male patients. The only
exception was one patient with cancer-related pain, who was excluded, and the next patient was
picked from the report. None of the patients using every tenth patient were duplicate patient
prescriptions. Of these patients, eighteen were prescribed hydrocodone-acetaminophen 10325mg, eight were prescribed hydrocodone-acetaminophen 5-325mg, and five were prescribed
hydrocodone-acetaminophen 7.5mg. Three patients were prescribed methadone 10mg,
methadone 5mg and morphine 60mg extended release. There was one prescription for morphine
100mg extended release, oxycodone-acetaminophen 10mg, morphine 15mg, oxycodone 30mg
immediate release, and a fentanyl patch (37.5mg/hr). There were six patients of the 39, or 15%,
who had a prescription for both a long acting and short acting opioid medications. On the report,
each of these six patients was coded to only one prescription but it was discovered on chart
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review that an additional opioid was present on the current medication list, thus accounting for
both a long and short acting preparation.
Site B: Post-implementation. Post implementation at site B, a total of 27 prescriptions
were written from February 19-March 19. Of these, there were nine prescriptions written for
hydrocodone-acetaminophen 5-325mg, four prescriptions written for hydrocodoneacetaminophen 10-325mg, oxycodone 15mg, and morphine 15mg. There were two prescriptions
written for oxycodone 10mg, morphine 60mg and methadone 5mg. Of the 27 prescriptions, there
were several duplicates. These were removed and the first chart listing per patient reviewed. On
analysis, three patients were excluded due to cancer related pain. This left a total of fourteen
patients included in review. The average age of those receiving opioids at site B was noted to be
58 years old. There were ten males and four females included in analysis.
Of these patients, eight received a prescription for hydrocodone-acetaminophen 5-325mg,
three received a prescription for hydrocodone-acetaminophen 10-325mg, two received a
prescription for methadone 5mg and one patient received a prescription for morphine 60mg
extended release. There were no instances where patients were on both long and short acting
opioids.
Pre/Post Morphine Milliequivalents
Site A pre/post implementation. An online calculator was utilized to assist in
calculation of morphine milliequivalents, as this is not identified as a discrete data field in the
electronic health record. Therefore, the total was calculated at the time of new prescription
written and it was assumed that the patient was taking the medication as prescribed. For instance,
if the prescription was written as 1-2 tablets, it was assumed that the patient was taking both
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tablets. If it was written as every six or every eight hours, it was assumed the patient was taking
as such.
Site A pre/post implementation. At site A, the pre-implementation total daily morphine
milliequivalents was noted to be seventeen among the 22 patients on the report. There was only
one patient above 50 mmEQ. Post implementation of the evidence-based toolkit, the average
daily morphine milliequivalents was noted to be twenty-five among the six patients reviewed.
Again, only one patient was noted to be above 50 mmEQ.
Site B pre/post implementation. At site B, the average daily morphine milliequivalents
was noted to be 85mmEQ/day among the 39 patients reviewed in the pre-implementation data.
There were fourteen total patients (36%) who were prescribed over 50 mmEQ/day and of these,
ten patients were prescribed over 100mmEQ/day. Post implementation, the average daily
morphine milliequivalents was noted to be 39mmEQ. Only two patients (14%) were prescribed
greater than 50mmEQ/day, with only one of these patients over 100mmEQ/day.
Co-Prescribed Benzodiazepine
During chart review, the DNP student reviewed the patient’s current medication list for
evidence of a prescription for benzodiazepine concurrent to the opioid medication prescribed.
This was noted regardless of name, strength, dose or indication. It was assumed with this review
and presence of benzodiazepine on the patient’s current medication list that the patient was
taking the medication as prescribed.
Site A pre/post implementation. At site A, pre-implementation data showed that three
out of 22 patients, or 14%, had a co-prescribed benzodiazepine concurrent to opioid prescription.
Post-implementation data showed a total of 1/6 (17%) patients received a co-prescribed
benzodiazepine.
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Site B pre/post implementation. At site B, a total of fourteen patients out of 39, or
36%, had a co-prescribed benzodiazepine at the time of opioid prescription. Following
implementation of the evidence-based toolkit, a total of 1/14, or 7%, patients had a co-prescribed
a benzodiazepine.
Urine Drug Screen
During chart review of patients receiving prescriptions for opioids, presence or absence
of urine drug screen within the last calendar year on file was reviewed to measure adherence to
organizational policy. This drug screen had to be present and could have been ordered at any
point during the duration of opioid therapy. The actual contents of the urine drug screen report
were not reviewed.
Site A pre/post implementation. Pre-implementation data showed there was a total of
twelve patients of the 22, or 55%, with a urine drug screen present. Post Implementation data
revealed that all but one patient (5/6) had a urine drug screen present (83%).
Site B pre/post implementation. There was a total of 25/39 patients, or 64% of patients
with a urine drug screen present in the pre-implementation data review. Post Implementation
data showed a total of 5/14 patients, or 36% of patients with a urine drug screen present on chart
review.
Medication Contract
Presence of a medication contract on file was another way to measure adherence to
organizational policy. This was reviewed both pre- and post-implementation to identify presence
or absence of the signed contract. This needed to be signed with the specific office, and not
necessarily the provider prescribing as the contract is applicable to all prescribers at the office
location.

ARIS FINAL DEFENSE

42

Site A pre/post implementation. It was noted at site A, twenty patients out of 22, or
91%, had a medication contract on file. Following implementation of the evidence-based toolkit,
all patients, or 100% had a medication contract on file.
Site B pre/post implementation. Pre-implementation data showed 53% of patients had a
medication contract on file for the 39 patients reviewed. After implementation, all but two out of
fourteen patients, or 88%, had a prescribing contract on file.
Opioid Start Talking Document
The state of Michigan implemented the Opioid Start Talking document to assist in
ensuring educated conversations are happening between patients and prescribers when opioids
are being issued. This was implemented in June of 2018 and is required for any patient receiving
a new prescription for opioids from a prescriber they do not have a previous relationship with.
For this measure, presence or absence of the opioid start talking document was identified. This
had to be signed with association to the prescriber listed in the report. To note, some of the
patients have long standing relationships with their prescriber and do not qualify under the need
for this document and some of the pre-implementation data was captured prior to June 2018,
which meant the providers would not have had this on file.
Site A pre/post implementation. For the Michigan Start Talking documentation, three
patients out of 22 or 14% of patients had this conversation noted on file. Post implementation, of
the six patients receiving opioids, two or 33% had a Michigan start talking form on file.
Site B pre/post implementation. At site B, two patients out of 39 or 5% had the
conversation noted on file. After implementation, six patients out of fourteen, or 43% had this
conversation on file.
Naloxone Co-Prescription
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For both pre- and post-implementation data, it was noted on chart review whether the
patient had been co-prescribed naloxone. This medication, which is the reversal for opioid
overdose, has been recently promoted by the CDC if a patient meets high risk criteria, including
total daily morphine milliequivalents over 50 seen as the suggested amount. Other risk factors
increase the likelihood of accidental overdose and should be considered when identifying need
for co-prescription, as well.
Site A pre/post implementation. There were no instances of co-prescribed naloxone
pre- or post implementation. To note, at site A, only one patient was prescribed over 50mmeQ
daily and would be considered as a suggested co-prescription, according to the CDC guidelines.
Site B pre/post implementation. At site B, there were no instances of co-prescribed
naloxone pre-or post-implementation. Of the pre- implementation fourteen patients would
qualify in the high-risk category suggesting co-prescription of naloxone, according to the CDC.
Post-implementation, only two patients fell into this high-risk category.
Use of Screening Tools Available in Epic
Part of the implementation of the evidence-based toolkit was discussion around the
documentation that should occur during the office visit to evaluate the patient’s overall goals and
function while prescribed opioids. There are several new tools the new EHR that make it easier
for providers to do this assessment within the realm of prescribing. This was not well known or
understood prior to implementation of the toolkit. Pre-implementation, it was expected that there
would likely be no utilization of screening tools. Screenshots were provided within the toolkit
and guidance was given in the opioid guideline on why these tools can be useful.
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Post-implementation revealed no instances of these tools being utilized within the health
record for the patients prescribed opioids at either site. This may be due to several factors,
discussed later in the results section.
Pain Management Referral and Diagnosis Categories
Pain management referral and diagnosis categories was helpful in the retrospective chart
review to see whether the prescriber had considered alternative or additional assistance in the
patient’s pain management. Current opioid overdose or diagnosis related conditions helped to
clarify the patient’s risk status, as the CDC indicates patients with history of opioid overdose are
considered in the category of patients suggested to receive co-prescribed naloxone.
Pre/Post Provider Prescribing Comfort Level
Site A and B pre/post combined data. Regarding provider practices, there were a total
of four providers who took the pre-comfort level survey at both sites and three providers returned
this survey for 75% return rate. These were pooled due to the small amount of responses. This
survey included a Likert scale to assist in determining a baseline of perceived knowledge of their
own prescribing habits and comfort level around prescribing in general. For the analysis, the two
sites were combined since the sample size of site A is small. A total of 35 points indicates the
provider strongly agrees to all points listed. For the pre-implementation data, the average score
was 28.75. The lowest ranked item was ‘I feel confident in understanding the organization’s
policies for opioid prescribing.’ The highest ranked item was an item that measured the
provider’s awareness of practice, which was ‘most of my patients on opioids have at least one
UDS per year,’ and ‘most of my patients are under a daily limit of 50 me.’
Three providers returned the post-analysis survey. The remaining provider was on
vacation during the post-implementation survey timeframe. The average score was 29. The
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highest ranked item was ‘most of my patients on opioids are under a daily limit of 50 mmEQ,’
which is an awareness of practice question. The lowest ranked item was ‘I find it easy to find
how many morphine milliequivalents for my patients who are prescribed opioids,’ which is a
confidence question.
Pre/Post Site A and Site B All Measures Comparisons
As each site had small sample sizes due to the short time frame post implementation, it
was not considered statistically relevant and there were limitations when considering the site’s
individually for statistical analysis. For the purposes of understanding whether the overall project
was successful regardless of site, all data was combined to provide total analysis over the project.
This is Pre-implementation, there were 61 total patients in review and 20 total patient’s postimplementation. Gender frequencies, short and long acting opioid frequencies for the entire data
set evaluation are listed in appendices T through V.
Co-Prescribed Benzodiazepine
There is not sufficient evidence to say that the proportion of patients that had
benzodiazepines differs pre- and post-implementation using Fischer’s Exact Test. (p = 0.1339).
Appendix W outlines the presence and absence frequencies for co-prescribed benzodiazepines.
Morphine Milliequivalents
There is not sufficient evidence to say that the total distribution of morphine
milliequivalents differs pre- and post-implementation using Wilcoxon Rank Sum test (S = 757, p
= 0.4954). See Appendix X for the evaluation of mmEQ distributions.
Urine Drug Screen
There is not sufficient evidence to say that the proportion of patients that got a drug
screen differs pre- and post-implementation using a Chi-square test (x2 = 0.2, p = 0.6551).
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Frequencies for both sites are listed in appendix Y. Pre- and post implementation comparisons
are listed in appendix Z.
Medication Contract
There is sufficient evidence to say that proportion of patients that had a medical contract
differs pre- and post-implementation using Chi Square test (x2 = 3.95, p = 0.0468). There were
90% of patients who had a contract in place post implementation compared to 67.2% preimplementation (see appendix AA and BB for medication contract frequencies and
implementation characteristics).
Michigan Start Talking Document
There is sufficient evidence to say that proportion of patients that had a start talking
document differs pre-and post-implementation using Fisher’s Exact test (p = 0.0022). Following
implementation, 40% of patients had a start talking document in place, compared to 8.2% prior
to implementation (see appendix CC and DD for Michigan Opioid Start Talking Frequencies and
implementation characteristics).
Naloxone and Screening Tools
There was no change in naloxone co-prescription or use of screening tools pre/post
implementation and therefore, these measures could not be included in statistical analysis.
Discussion
The CDC considers what is known from epidemiology research about benefits and harms
related to opioids in consideration of recommendations for prescribing patterns, including high
dose therapy, co-prescription, and others. The CDC was the primary body of evidence used for
the evidence-based toolkit and provided guidance for the measures in this project. Several key
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points were considered when looking at the relevance to the purpose of this project and with
evaluation of the association between the interventions and outcomes.
Morphine Milliequivalents
In most studies, higher dose opioid therapies are associated with increased
overdose risk (Dowell, Haegerich, and Chow, 2016). In several studies reviewed by the CDC,
fatal overdose was associated with opioid mmEQs that were higher, including those above
50mmEQ. The results of this implementation indication there is risk for unintentional overdose
associated with patients at both practices, and this was recognized and mitigated with the
evidence-based toolkit. The post implementation data for combined practices was not statistically
significant for reduction in total mmEQ. However, with combining of both sites, there was a
reduction of mmEQ/day of 26.4 and at site B, there was a reduction in mmEQ/day by 46. While
this is not statistically significant, it is clinically relevant in reduction of harm by risk of
unintentional overdose to patients in these practices.
Additionally, not included in the metrics but notable was the consideration of importance
around formulation of opioids, with extended release/long acting (ER/LA) and short acting
prescription. The FDA agrees that there are several serious risks associated with ER/LA opioids
and documents the indication or this class of medication being pain management severe enough
to require long term, daily opioid treatment for whom other options are not effective (US
Department of Health and Human Services Food and Drug Administration, 2013). Site A did not
assume this risk for any patients reviewed either pre- or post-implementation, but site B did have
15% of patients reviewed on both ER and short acting medications pre-implementation. After
implementation of the evidence-based toolkit, which included literature on the risk for long
acting opioids, there were no patients prescribed both long and short acting medications at either
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site, which is again considered very clinically relevant in reduction of overall risk status for
patients on opioids.
Co-Prescribed Benzodiazepine
In epidemiologic studies, the CDC found that concurrent use of benzodiazepines and
opioids might put patients at greater risk for potentially fatal overdose (Dowell et al., 2016).
Within the chart review, it was noted whether the patient had a prescription for benzodiazepine
on the medication list, but duration, dose or indication was not considered. In combined data, it
was notable that there was not a statistically significant change in co-prescribed benzodiazepine
but both sites had a reduction of 18% of co-prescribed benzodiazepines. Like mmEQ/day, site B
provided what appeared to be a large practice change regarding this measure, with an overall
reduction of 29% of patients on co-prescribed benzodiazepines. Site A did have an increase in
the percentage of patients on benzodiazepine therapy, but the small sample size was likely the
cause for this finding.
Start Talking and Medication Contracts
The Opioid Start Talking Document and medication contract were enacted to
assist in a patient’s increased understanding of the risks of opioid therapies. These factors are
part of the organization’s suggested guideline for opioid prescribing and were included in this
project to assist in increased adherence to this measure. Both the Start Talking Document and
Medication Contract saw statistically significant change post intervention. The Start Talking
document, as indicated previously, was enacted after the period of review for some patients.
There were several considerations for use of this document, as well, as patients on long-term
therapies with the same provider would not fall into the legislation of need to have the document.
Urine Drug Screen
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There are benefits of urine drug screen testing including the ability to identify patients
who might be at higher risk for opioid overdose or opioid use disorder (Powell et al., 2013). The
use of urine drug screen was highly compliant at site A both pre-and post-implementation. The
use of urine drug screen decreased in compliance at site B post implementation. This could be
due to a variety of factors, including consideration of whether reduced mmEQ and less patients
with ER/LA and short acting combinations had an influence on this factor. Further, as discussed
previously, duration of drug was not part of the review, so if a patient was started on short
duration (<7 days) opioids, it is unlikely to be associated with a urine drug screen.
Naloxone and Screening Tools
As noted in the results section, there was no change in naloxone prescribing or screening
tools post intervention. There are several limiting factors to the implementation of both
measures. Risk mitigation with co-prescription of naloxone provides limited evidence in the
literature surrounding primary care. However, there is success through distribution through
community-based programs offering prevention services for substance users and there has been
an association with decreased risk for opioid overdose death at the community level.
The concepts around co-prescribing in primary care are new for most providers. This
generated the most questions regarding the toolkit discussions. There was information in the
toolkit on the importance of naloxone and patient education was included. However, there was
not information included on pharmacy or insurance information for obtaining the medication
within a reasonable cost. Additionally, at time of implementation there were not quick, patient
friendly videos on naloxone administration targeted for patient and families. It takes time for the
provider and/or medical assistant to properly educate the patient on identification of overdose
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and how to appropriately administer the medication. With limited time during the primary care
visit, this poses a challenge. Continued work is planned for this education and standard work.
Screening tools are identified by the CDC as useful but there were mixed results in the
review of literature. The EHR provides availability to these tools and screen shots were given in
the toolkit to providers but it was not physically shown to providers where or how these were
accessed, assuming providers had the knowledge and use of epic to implement these on their
own. This assumption may have led to no change in post-implementation data. Additionally,
most of the opioid prescriptions in the post data period were not associated with an in-office visit
and instead was with a phone call from the patient for a refill request. The message was sent via
medical assistant or RN to the prescriber, who reviewed the chart data and refilled. Use of
screening tools in these cases, would not be indicated.
Provider Comfort Level in Prescribing
The CDC identifies that many prescribers lack confidence in the ability to prescribe
opioids safely, to predict or detect prescription drug abuse and to discuss this with their patients
(Dowell et al., 2016). Further, according to Dowell et al. (2016), most clinicians are not
consistently using practices intended to decrease the risk for misuse, including urine drug testing,
opioid treatment agreements and Prescription Drug Monitoring Systems (PMPD’s). It was
identified that there was slight change pre- and post with provider comfort level and awareness
of organizational policy, but this change was not significant. This Likert style survey was created
by the DNP student and thus could have been subject to limitation by question strength and
applicability to the desired outcome. See appendix EE for the survey characteristics.
Informatics Change
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As mentioned previously, part of the implementation was an informatics change that was
requested by the DNP student that would aid in provider use of tools in the EHR. This change is
not discussed in detail in the project discussion, due to the challenges in implementation of this
change. The student presented across several different leadership forums to discuss the idea,
which was a best practice advisory (BPA) that would allow for provider recognition of high-risk
patients in the EHR. This BPA would look across several factors and pull together the alert to the
provider on the total daily mmEQ as well as recommendations for naloxone, as needed. Further,
there would be ease of ordering this medication through a few clicks.
During implementation of the project, the DNP student was simultaneously working
through this change. The BPA was approved through these several presentations, including to
leadership, the Primary Care Informatics change management group, and with information
services. However, it was decided by the organization that this request would be grouped
together with other, similar EHR changes that would be taking place with the opioid initiatives
across the organization. Therefore, progress was halted, and this could not go forward within the
timeframe desired by the student. There will still be continued work toward finishing the
initiative in the ‘next steps’ section of the paper.
Site ‘A’ Overall Learnings
There were several points of discussion following review of the results revealed in the
current practices of opioid prescribing at the site. At site A, it was identified that there was
generally good practice for opioid prescribing, with some overall suggestions for improvement.
Opportunities included ensuring providers were considering use of a screening tool to assist with
recognition of their patient’s overall goals for pain and function. Annual drug screening and use
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of the Michigan Start Talking document were additional suggestions for improvement of the
individual practice.
The strengths of site A included the fact that only a small number of patients had a coprescribed benzodiazepine, there was an overall low total daily morphine equivalence, there were
use of referrals in place to assist with the patient’s pain management related conditions and use
of short acting medications rather than longer acting, which is recommended by the CDC’s
guidelines. There is also good compliance with medication contracts.
Site B Overall Learnings
At site B, there are also areas of strength and opportunity. Strengths include the high
compliance with urine drug screen and compliance with medication contracts. There are several
pain management referrals and referrals elsewhere to assist with pain. While there was
significant improvement with prescribing practices with overall mmEQ and co-prescribed
benzodiazepines, there is still some opportunity for improvement in this area. No patients had
naloxone prescribed, which is recommended by the CDC if a total daily MMEQ is listed about
50, which still exists for some patients. Of significant relevance was that there was a complete
reduction in instances with both long and short acting preparations post-intervention. Site B saw
many different improvements clinically, though not statistically significant.
Barriers
There were several barriers hindering the success of the project implementation. First, the
limitation in the epic EHR provided gaps in the provider’s ability to quickly find morphine
milliequivalents for their patients and to identify high risk patients for overdose. This was
outlined in the post survey and apparent in the DNP student’s review of patient charts.
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Additional barriers included the challenges in implementation due to limited availability during
the office day of providers, including vacation schedules and provider turn-over in the office.
The organization is working on another facet of the evidence-based toolkit which would
have provided some relevance and assistance to the use of this project. An interdisciplinary
committee is putting together intentional tools and algorithms to aid the provider in weaning,
consideration for substance use treatment, and how best to navigate and approach different types
of pain a patient presents with. The algorithms provide suggestions and treatment alternatives to
pain management. This provided a barrier to the project because these tools were not yet
available to prescribers. Therefore, they needed to navigate the complexities of weaning and
referral, without prior guidance and this can prove to be an obstacle in rural primary care. There
is continued work on this piece and is provided in the ‘next steps’ portion of the paper.
Limitations
Clinician and patient values are difficult to discern and are not captured in the data.
Patients all have varying clinical presentation, history and indications for use. There are not
discrete data fields in the EHR to evaluate the extent of this discussion or consideration for
opioid prescription. There were not qualitative measures obtained to assist with the recognition
of these factors and had these been present could have been a factor to assist in the understanding
of the patient/provider values in opioid prescribing. Further, diagnosis, duration of therapy, comorbidities and age were not accounted for in the design. Individualized factors prove to be
important pieces in the opioid prescribing puzzle, so it is difficult to discern how these pieces of
information would have contributed to the project outcomes.
Indications for opioid prescriptions were not considered regarding prescribing patterns.
This is another important piece in understanding the overall picture of the patient’s need for
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opioids. The exception to this was the removal of cancer patients in the data review. Additional
considerations that have been found to have considerable connections to opioid prescribing
include mental health and substance use history and these factors were not assessed. Many
people have been found to have a large emotional connection with their medications and while
these conversations were likely happening during the visit, this was not addressed.
Among chart review findings, it was noted in the notes for refills that many patients were
said to be weaning from their opioid medication, which was not captured in the data.
Additionally, many patients had documentation that there were attempts at other pain modalities
prior to starting opioids, which is an important concept to consider. For example, many patients
had tried non-opioid alternatives such as anti-inflammatory medications, Tylenol, non-opioid
pain patches, and medications such as tricyclic antidepressants and nerve pain medications to
control pain and this was noted in the documentation. These alternatives were not captured in the
data and could have been an important factor to understanding why opioids were the best
alternative for the patient with significant pain, resistant to other therapies.
Tabulation of the total mmEQ for patients was challenging to include in the review.
Many pain medications are listed as needed (PRN) or are written for one to two tablets for use,
which makes it difficult to assess what the patient is taking when attempting to capture their total
daily mmEQ. Therefore, the DNP student had to assume that the patient was taking the
medication as prescribed, as there was no way to capture the amount taken in a discrete data field
from the electronic record. This meant that the mmEQ described in the data was unlikely to be
completely accurate.
Site B has a physician that specializes in pain management, addiction, and is a
Buprenorphine provider for the community. He also serves as a palliative care and hospice
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provider. While cancer and palliative care patients were excluded, there were no exclusions
made for patients with pre-existing addiction concerns or any exclusions for chronic,
longstanding pain. There was no Buprenorphine listed on the opioid report. Therefore, as a
limitation of the study, it’s likely expected that this provider would possibly have higher daily
mmEQ tabulations due to the nature of the work he does and the patient population he sees.
Additional limitations included the recent provider turnover in the office, which meant
that some providers were on the pre-implementation report but did not have any prescriptions
listed after implementation. It was considered that many of the patients being prescribed
medications are likely to remain with the practice after provider absence, so these provider’s
practices were not excluded from the pre-implementation report.
The Michigan Start Talking Document only became a requirement for the state middle of
the audited year, leaving some patients to have decreased compliance in this, which was
expected. Additionally, use of this document is not easy to understand with chart review as far as
whether this is necessary during the specific patient’s case. It would be a more detailed and
extensive chart review to understand the patient/provider relationship and this was not
completed. Therefore, presence or absence of this document was tabulated but more
consideration should go into the significance of this document.
One of the most important factors is the fact that opioid practices have undergone large
changes between the beginning of 2018 and 2019 because of state and organizational initiatives.
There were several forums outside the work of this project where providers could learn about
opioid legislation changes, CME offerings and opportunities where there was additional
education provided. Therefore, the significance of their changes in opioid prescribing practices
must take into considerations other opportunities for learning.
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The project had a short implementation period and took place at rural locations with very
few provider staff present. Additionally, there were transitions of providers before and during
implementation of the toolkit, making consistency challenging. Another limitation included the
small amount of data collected to reveal to ‘pre-implementation’ data and the fact that this
retrospective review took place following the intervention. This was a limitation because
providers could not see pre-prescribing trends and data to help drive the intervention. This was
presented to them after implementation and results were available.
Finally, there was a limitation realized with the provider survey. Questions 1-6 on the
survey are responses that are expected and/or desired to increase post implementation. It was
discovered that question 7 is written in such a way that the responses would be expected to
decrease following intervention. This was somewhat contradictory in the provider’s view of the
survey and made data analysis for this survey difficult. Further, the small amount of responses
compared to eligible prescribers, as well as even smaller amount of responses post
implementation created limitations.
Summary
According to the Centers for Disease Control and Statistics (2018), drug overdose deaths
continue to rise in the United States. Every day, an average of 130 Americans die from opioid
overdose, and the number of opioid overdose deaths is six times higher than in 1999 (CDC,
2018). The nature and significance of this problem is astounding and requires unique attention
paid by all health care providers, including those in primary care. Unintentional overdose should
be considered a factor and should not be ignored.
There are many relevant studies to how primary care providers fit into the puzzle of
ensuring safe prescribing habits for patients. Many studies examine the impact of increased
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provider knowledge of safe opioid practices, which can positively influence prescriber habits.
Additional studies identify cost savings with implementation of targeted education to providers
on opioid prescribing (Quanbeck et al., 2018). Relevant studies identify a statistically significant
reduction in morphine-equivalent daily dose observed compared to control when a targeted
implementation is put in place. There are also known increases in adherence to recommended
urine drug testing, use of treatment agreements, and opioid-benzodiazepine co-prescribing rates
with targeted interventions (Quanbeck et al., 2018). Additional relevant studies by McCracken et
al. (2016), Liebschutz et al. (2017) and Gaiennie and Dols (2018), found increased intention to
prescribe using safer habits, reduction in total opioid prescriptions, a reduction in daily
morphine-equivalent dosing, increased referral to pain management, as well as increased
awareness of strategies to provide more regular assessment and re-assessment of pain scores and
screening for patients on opioid therapies. Therefore, the literature does support such
intervention.
There were several models used to guide the intervention, including the Chronic Care
Model and Kotter’s Eight Step Model for Leading Change. The intervention utilizes the
principles of each model to assist in the understanding of how the intervention will be successful
at the chosen site for implementation. Several assumptions were used to develop the
intervention, including the idea that the organization is moving in the way of improving opioid
prescribing practices leading to desired changes among providers, the idea that most providers
could benefit from increased knowledge and awareness of safe opioid prescribing practices and
there are needed changes in the EHR to make the work of the provider more efficient.
The intervention was expected to work because of the use of evidence to drive practice
change. Providers use evidence every day to guide the care of their patients in the care they
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provide in other ways. This is not a new concept in primary care medicine and is a driving force
in the care of patients. Due to the extensive nature of the changes in the state of Michigan
regarding opioid prescribing as well as the desire of the organization to match these changes, it is
assumed that the intervention will only help drive providers to become more aware of
organizational and state/national policy. Specific aims of this project include identifying ways
the literature and best practice can guide evidence-based care at the bedside, ensuring there is
opportunity to have the needed resources available for providers at their fingertips. The purpose
of this project and of this paper is to outline the project, including a description of the methods,
intervention, approach, measures and analysis of the project.
Implications for Practice and Further Study in the Field
The topic of opioids is one that has wide relevance in primary care practice. This ability
for a primary care prescriber to care for patients holistically is a well understood role of the DNP
prepared nurse. It was the goal of the DNP student to learn more about safe opioid prescribing
through this evidence-based project. While there are many varied practices in primary care for
caring for patients, and there is individualized care that requires unique attention to a patient’s
specific needs. Further, there is a desire and need to understand the part of the practitioner in
keeping a patient safe from harm, including risk for unintentional overdose.
While not statistically significant, there were many lessons learned by the reduction in
overall mmEQs and benzodiazepine co-prescribing habits and these provide clinical relevance in
the reduction of overall risk for overdose in patients of the primary care practices. Clinical
relevance in the DNP student’s project prove of exceptional value in what the project can
provide to patients and the unique care that is provided.
Support, Sustainability and Next Steps
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Sustainability of the DNP project is also an important concept to consider, as after
graduation, there should be a way for the project site to maintain the direction and momentum
that has been gained by the student enacting the project. There are several next steps to consider
for the project. First, the informatics change with the best practice advisory will continue and the
checklist can be updated and used at the bedside whenever there is a legislative or organizational
change that needs to be added. Additional work around opioid tools are also being vetted, with a
dashboard in the works to assist providers.
Continued support and work on the algorithms mentioned previously will require some
additional work related to this project. This will include, but is not limited to sample weaning
schedules, opioid use disorder treatment options and referrals, and alternative pain management
pathways with alternative medications and non-pharmacological strategies. This strategy should
help immensely in provider comfort and awareness of care for patients on opioids.
The final results were presented in April 2019 to the site, as well as the Steering
committee. The DNP student provided handoff to the director of operations at the site, who will
continue work on implementation of the toolkit across the system. The information is valuable
for the organization to continue forward so this formality will take place to ensure the
organization has all materials desired to be put forward to providers.
Dissemination of Outcomes
Dissemination of the results included several presentations to key stakeholders across the
organization and the university. The student has already had an opportunity to share portions of
the project along the way. In October, a presentation to both the local newspaper and local news
was conducted by the student to bring awareness to both the project and the opioid epidemic.
Additionally, the student also presented at a local conference. The purpose of this presentation
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was to engage the public and other health care professionals on the topic of opioids, including
current and local trends on the topic.
The student participated in the DNP Defense, which is a presentation to faculty and peers
and provides an opportunity for discussion and review of the overall scope and results of the
project. Additionally, the student presented at the monthly all provider meeting at the
organization, which prefaced spread of the materials to other providers in the practice.
Additional presentations included to the Opioid Steering Committee at the site, as well as
leadership committees that were requested. The results were shared both individually and
collectively across the provider groups at the specific sites for implementation.
Reflection on DNP Essentials
While the focus of the DNP degree is expertise in clinical practice, there is additional
emphasis placed on what are considered the Essentials for Doctoral Education for Advanced
Nursing Practice by the AACN. These essentials include leadership, health policy and advocacy
and information technology. The goal of the DNP prepared nurse is to identify those essentials as
significant to the character of learning while completing the DNP degree. These essentials will
aid in the overall ability of the DNP prepared nurse to enter clinical practice in a way that
prepares them for the additional scope and provision of their role. It helps to formulate the type
of practitioner the DNP prepared nurse wishes to become.
The goal of the DNP essential completion was to initially identify the essentials that were
of lesser competency in the DNP student’s personal abilities. This took place over a detailed
review of each competency and how that specific competency could be achieved. Over the
course of several semesters, the student worked to address and improve the ability to achieve
each competency, including continued self-reflection at the beginning of each semester. The
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student would seek opportunities that provided the ability to better knowledge and understanding
of the principles of the DNP project, as well as those experiences that contributed to improving
the ability to be a well-rounded DNP prepared nurse. The experiences ranged from working side
by side with other providers and practitioners, to volunteerism, to seeking out lectures,
conferences and webinars to broaden the knowledge base. The student worked with a clinical
ethicist at a local health care organization to better assist in understanding the various ethical
challenges associated with healthcare and how the DNP fit into the role of an ethically competent
professional.
Additional experiences included frequent volunteerism with the Grand Rapids Red
Project. This role was paramount to the student’s project in the way of learning to reduce the
stigma associated with care and assistance of people fighting addiction. This helped the student
to change language and assumptions related to the care of patients who use and potentially misuse opioids and other substances. The student provided several overdose prevention trainings to
area inpatient and outpatient drug and alcohol rehab facilities, local universities and provided one
on one training during walk-in hours across several counties in Michigan. Volunteerism at the
Hall Street location in Grand Rapids provided the opportunity to work with and learn from
people who have current and previous addiction, including how best to serve them and their
needs. The DNP student learned to “meet people where they are at” which is a key strategy and
vision of the Red Project and learned to discuss sensitive matters in ways that are more caring
and non-judgmental. This carried over into the student’s personal employment as an Emergency
Room nurse and provided value in everyday interactions with patients that are often otherwise
stigmatized in health care. This volunteerism provided some of the richest experiences the
student encountered during the immersion opportunities.
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Conclusion

The opioid crisis has reached epidemic proportions. Learning and understanding that
addiction to opioids and unintentional overdose are a driving factor in this epidemic left the DNP
student looking for ways to help reduce this risk. The evidence-based approach to creation of the
toolkit helped the student to engage the literature and find best practice in opioid prescribing. It
also assisted in recognizing the organization’s desire and need for opioid prescribing guidelines
that are centered around evidence. Entering practice with the knowledge that this project has
created is instrumental in ensuring there is the ability to carefully and safely prescribe in the
future.
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Appendix A

PRIMSA Flow diagram of search selection process  
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Appendix B
Table of Evidence

Author
(Year)
Purpose

Design (N)

Gaiennie
and Dols
(2018)

Quality
intervention

Liebschutz Randomized
et al. (2017) Controlled
Trial
Intervention
to identify
provider
adherence
to
guideline.

Inclusion
Criteria

Intervention vs
Comparison

Primary
Pre-and postcare NP and implementation
physicians
data was
in one
collected after
practice
an information
fair, trainings
and quality
meetings.
There were
also 1:1
meetings with
each provider.

Physicians
and Nurse
Practitioners
who had at
least 4
patients 18
and older on
opioid
therapy.

4 interventions
vs. control
1). Nurse care
manager
2). Electronic
education
3). Single
academic
session
4). Academic
and online
platform.

Results

Following
intervention,
there was a
10% reduction
in opioid
prescriptions
written and 7%
of patients
referred to pain
management
for treatment.
At 1 year,
intervention
patients were
more likely
than controls to
receive
guidelineconcordant
care, to have a
patient provider
agreement and
to undergo at
least 1 urine
drug screen.
Intervention
patients were
more likely
than controls to
have a 10%
dose reduction
or opioid
treatment
discontinuation.

Conclusion

Targeted
education and
guideline
implementation
can increase
patient safety
and influence
outcomes.

A
multicomponent
education
intervention
improved
guidelineconcordant care
but did not
decrease early
opioid refills.
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There was no
difference in
early fill of
prescriptions
between
groups.

McCracken
et al.,
(2012)

Randomized
Controlled
Trial

Quanbeck
Randomized
et al. (2018) controlled
trial

All participants
General
had a 1-hour
practitioners training
at Primary
followed by
Care
either:
Research
Network
1). Training
based on
acceptance and
commitment
theory, or,
2), standard
training

Overall, there
was an increase
in knowledge
of opioid
prescribing for
chronic pain
and decreased
concerns
related to
prescribing
following
training. There
were no
changes in
provider
reported
wellbeing.
There was a
greater increase
in intention to
use prescribing
guidelines.

Primary
care
providers
with
patients
being
treated for
chronic pain

At 6 months,
statistically
significant
improvements
were noted in
intervention
clinics in the
percentage of
patients with
mental health
screens,
treatment
agreements,

Four
intervention
clinics versus
four control
clinics that
received one of
several
options:
1. Audit and
feedback, 2.
Academic
detailing,
external

Well-designed
training can
increase
knowledge of
opioid
prescribing.

There is an
opportunity to
increase safety
and efficiency
of opioid
prescribing with
intervention
versus none.
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facilitation

Tournebize,
et. al (2016) Systematic
review

Prescribers
with
adherence
to at least
one opioid
reduction
strategy

Von Korff
QuasiPhysicians
et al. (2016) experimental part of
design
health group
in
Washington
state

N/A

Statewide
guidelines for
change in
opioid
prescribing
versus health
plan group
practice
changes and

urine drug tests
and opioidbenzodiazepine
co-prescribing.
At 12 months’
morphineequivalent daily
dose was
significantly
reduced in
intervention
compared to
control. There
was a cost
savings of
$7345 per
clinic.
Less than 50%
of providers
assess pain
intensity using
a pain scale and
often consider
transdermal
fentanyl as a
safe alternative
in opioid naive
patients.
Further,
providers do
not always
discontinue
opioids if they
are ineffective
in relieving
pain.
Groups that
received both
guidelines had
reduced opioid
days and
reduced
morphine
mmeQ versus

There are
opportunities to
increase
provider
adherence to
safe opioid
prescribing
practices.

Additional
information
increases
physician
adherence to
practice
changes.
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statewide
guidelines.

that of the
statewide
guidelines
alone.
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Appendix C Burke Litwin Model
External
Environment

Leadership    
Mission  and  
Strategy    

Organizational  
Culture    
Management  
Practices  

Structure    

Systems  (Policies  
and  Procedures)  

Work  Unit  
Climate  

Task  and  
individual  skills    

Motivation    

Individual  Needs  
and  Values    

Individual  and  
Organizational  
Performance      

Figure 1. A model of organizational performance and change. Re-created from “A Casual Model
of Organizational Performance and Change,” by W. W. Burke and G. H Litwin, 1992, Journal of
Management, 18, 528. Copyright 1992 by Southern Management Association
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Appendix D
SWOT

Strengths
•   Engaged Leadership including supervisor,
manager, director
•   Low provider and staff turnover
•   Consistent Medical assistant/prescriber
relationship
•   Consistent providers in the practice
•   Process improvement in place
•   DNP prepared NP

Opportunities
•  
•  
•  
•  

Consumer demographics
Recent state policy changes
Organizational policy changes coming
Increase quality of care with evidencebased care solutions
•   Part of a larger health care organization
•   Reduce risk of overdose

Weaknesses
•   High panel load for each provider
•   Patients on long term opioid regimens
•   No current EHR notification for high
MMEQ
•   Many screening tools already in place
•   Recent EHR change with large focus on
recent big changes.

Threats
•   Patient satisfaction regarding pain
management regimens and their
satisfaction with pain control.
•   Patients unaccepting of changes in long
term regimens.
•   Limitations in health literacy in the
community
•   Limited transportation
•   High no show rate at the office
•   Staff and provider buy in to practice
change.
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Appendix E: Letter of Support from the Site
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Appendix F: Chronic Care Model

Levenson,  J.  (2017).  Behavioral  health:  moving  to  a  chronic  care  model  helps  payers,  providers  and  patients.  MAP  
Health  Management.
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Appendix H: IRB Site Specific

ARIS FINAL DEFENSE
Appendix I: IRB Grand Valley State University

79

ARIS FINAL DEFENSE

80
Appendix J: Additional IRB Approvals
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Appendix K: Data Points

Data Variables to Be Collected for Project Before and After Toolkit Implementation

1.  
2.  
3.  
4.  
5.  
6.  

Age
Gender
Short acting opioid name, dose, strength, regimen and length of time on medication
Long acting opioid name, dose, strength, regimen and length of time on medication
Benzodiazepine (presence or absence on medication list at time of opioid prescription)
Screening tool-PEG, SOAPP, ORT (presence or absence on medication list at time of
opioid prescription)
7.   Morphine milliequivalents (calculated by me using online calculator)
8.   Urine drug screen presence or absence
9.   Medication contract presence or absence
10.  Start talking document presence or absence
11.   Referral to pain management
12.  Diagnosis related to opioid use
13.  Diagnosis of opioid overdose
14.   Provider pre- and -post comfort level with guidelines.
15.  Total provider prescriptions per month
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Appendix L:

Sample pre- and post-survey for Prescribers/Office Staff
1 = strongly disagree

2 = disagree

3 = neutral

4 = agree

5 = strongly agree

Please rate the following on a scale of 1 to 5.
1.   I feel confident in understanding the legislative changes in the state of Michigan with
regard to opioid prescribing.
2.   I feel confident in understanding the organization’s policies for opioid prescribing.
3.   Most of my patients on opioids have signed opioid prescribing contracts.
4.   Most of my patients on opioids have at least one UDS per year.
5.   Most of my patients on opioids are under a daily limit of 50 mmEQ.
6.   I find it easy to know how many morphine milliequivalents for my patients who are
prescribed opioids.
7.   I think patients could use more education with regard to opioid prescribing changes.
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Appendix M:
Timeline for Implementation

Item

Projected Timeline

IRB Determination

Granted December 3, 2018

Proposal Defense

November 5, 2018

Toolkit creation

12/15/2018-1/15/2019
*month long review of literature, approvals, putting together
education.

Implementation date/education

February 18 (site A)

and support

February 19 (site B)

Pre-data review

Week of March 5, 2019

Return to site for provider updates
and questions/feedback

Week of March 18, 2019

30-day implementation data

Week of March 18, 2019

Presentation of data to site

April 2019

Final Defense

April 1, 2019
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Appendix N: Informatics Change Request
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Appendix O: Table of Evidence from Toolkit

Guideline  Reference  Number  
  
  
  
  
  
  
  
  
  
  
5.1  Providers  will  prescribe  opioids  
based  on  evidence-‐based  guidelines  and  
in  accordance  to  state  law.  

5.1.1  Providers  should  consider  non-‐
opioid  alternatives  prior  to  starting  
opioid  therapy.    

5.2.1.  Providers  prescribing  should  
consider  opioid  therapy  if  the  benefits  
for  pain  and  function  outweigh  patient  
risk.    

5.1.3.   Treatment   goals   should   be  
established  with  patient  prior  to  starting  
opioid  therapy.  
  

  
Evidence  
State  Law  in  Michigan  
Public  Act  246  of  2017  (June  1,  2018)  
§   Must  discuss  risks  of  opioids  with  parent  or  guardian  of  minors,  
including  overdose,  addiction,  danger  of  mixing,  and  mental  health  
connection  with  addiction.      
§   Obtain  signature  of  parent  or  guardian.  If  not  a  parent  or  guardian,  
cannot  prescribe  more  than  single  72-‐hour  supply  to  minor.    
§   For  adult  patients:  Must  discuss  addiction  risk,  disposal  information  
and  that  delivery  of  a  controlled  substance  is  a  felony  under  Michigan  
law.    
§   If  patient  is  pregnant,  must  disclose  risk  to  fetus.    
Public  Act  248  of  2017  (June  1,  2018)  
§   Before  prescribing  or  dispensing  a  controlled  substance  to  a  patient,  a  
licensed  prescriber  shall  register  with  MAPS.    
§   Before  prescribing  or  dispensing  a  patient  a  controlled  substance  in  a  
quantity  that  exceeds  a  3-‐day  supply,  a  licensed  prescriber  shall  
obtain  and  review  a  MAPS  report.      
Public  Act  250  of  2017  (March  27,  2018)  
§   Requires  a  health  professional  licensee  or  registrant  that  treats  a  
patient  for  an  opioid-‐related  overdose  to  provide  the  patient  with  
information  regarding  substance  use  disorder  services.    
Public  Act  251  of  2017  (July  1,  2018)  
§   A  prescriber  treating  for  acute  pain  shall  not  prescribe  more  than  a  7-‐
day  supply  of  an  opioid  within  a  7-‐day  period.    
  Considerations  to  be  used  include:    
§   NSAIDs,  TCAs,  SNRIs,  anti-‐convulsant  medications    
§   Physical  therapy,  exercise,  weight  loss    
§   CBT  behavioral  treatments    
§   Procedures  such  as  intra-‐articular  injections  
§   Ice  or  heat,  elevation,  immobilization,  rest,  relaxation  
§   Also  consider  treating  sleep,  depression,  anxiety,  or  mood  (avoiding  
benzodiazepines)      
§   Benefits  of  long-‐term  opioid  therapy  for  chronic  pain  is  not  well  
supported  by  the  evidence.    
§   Short-‐term  benefits  are  small  to  moderate  for  pain  but  inconsistent  
for  function.    
§   Insufficient  evidence  for  long-‐term  benefits  in  lower  back  pain,  
headache  and  fibromyalgia.
Not  all  acute  pain  requires  treatment  with  opioids  and  it  is  important  to  
consider  that  pain  varies  among  patient  demographics,  cultural/ethnic  
factors,  prior  history  of  alcohol,  drug  or  opioid  use,  and  history  of  mental  
health  conditions  (anxiety  and  depression).    
  
§   Opioids  should  be  prescribed  in  no  greater  quantity  than  required  for  
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expected  duration  of  pain  that  is  severe  enough  to  require  opioids.    
§   The  goal  for  acute  pain  should  not  be  zero  pain,  but  rather  tolerable  
that  allows  for  optimal  physical  and  emotional  function.    
5.1.4  The  risks  should  be  discussed  with   See  Michigan  Public  Health  Law  246  of  2017  (above).  This  takes  place  in  the  
the  patient  or  the  patient’s  
form  of  the  Start  Talking  Document  at  Spectrum  Health.    
representative  prior  to  and  during  opioid  
§   The  form  should  contain  the  medication  name  and  quantity  
therapy.    
prescribed.      
§   The  consent  form  should  be  completed  for  each  opioid  medication  
prescribed  and  updated  annually  if  the  prescription  is  still  active.    
§   Any  licensed  personnel  can  have  the  discussion  around  opioids  with  
adult  patients;  pediatrics  should  be  discussed  directly  with  the  
provider.    
5.1.5.  Providers  should  start  with  the  
Opioids  should  be  prescribed  in  the  lowest  effective  dose  for  the  shortest  
lowest  effective  dose  of  short-‐acting  
duration  necessary.    
opioids  when  initiating  opioid  therapy.    
§   Taking  opioids  for  acute  pain  is  associated  with  a  greater  likelihood  of  
long-‐term  opioid  use.      
§   The  greater  the  amount  of  initial  opioid  exposure  (higher  total  dose,  
longer  duration  of  prescription)  is  associated  with  risk  of  long-‐term  
use,  misuse  and  overdose.    
5.1.6.  Before  prescribing  or  dispensing  
The  provider  should  be  equipped  to  deal  with  a  patient  presentation  and  how  
an  opioid  to  a  patient,  a  licensed  
other  medications  interfere  with  the  patient’s  current  opioid  therapy.  
prescriber  shall  ask  the  patient  about  
Overdose  risk  is  increased  when  medications  are  mixed.    
other  controlled  substances  the  patient  
§   Some  points  to  consider:  some  patients  are  under  the  impression  that  
may  be  using  and  document  this  in  the  
a  stimulant  medication  will  offset  the  effect  of  opioids  but  instead  
medical  record.      
these  tend  to  increase  risk  of  overdose.    
§   Alcohol  use  should  be  assessed  and  risk  factors  of  overdose  with  
alcohol  and  opioids  should  be  discussed.    
§   Having  an  open  line  of  communication  is  key  with  patients  who  may  
be  on  other  substances.  Taking  time  to  understand  the  reasons  
behind  their  additional  substance  use  as  well  as  their  methods  may  
clue  the  provider  into  whether  this  is  illicit  use  or  use  to  better  
control  pain.    
5.1.9.  Careful  assessment  of  individual  
Use  extra  precautions  when  increasing  to  >50MME  per  day,  such  as:  
benefit  and  risk  should  be  considered  
§   Monitor  and  assess  pain  and  function  more  frequently    
before  increasing  dosage  to  
§   Discuss  reducing  dose  or  tapering  and  discontinuing  opioids  if  
>50MME/day  and  a  provider  should  
benefits  do  not  outweigh  the  harms.    
generally  avoid  increasing  dosage  to  
§   Offer  naloxone  (see  5.1.10).    
>90MME/day.    
  
How  much  is  50  or  90  mmEQ/day  for  commonly  prescribed  opioids?  
50mmEQ/day    
50mg  of  hydrocodone  (10  tablets  of  hydrocodone/acetaminophen  5/300).  
33  mg  of  oxycodone  2  tablets  of  oxycodone  sustained-‐release  15mg)  
12  mg  of  methadone  (<3  tablets  of  methadone  5mg)  
  
90mmEQ/day    
90mg  of  hydrocodone  (9  tablets  of  hydrocodone/acetaminophen  10/325)  
60mg  of  oxycodone  (2  tables  of  oxycodone  sustained  release  30mg)  
20  mg  of  methadone  (4  tablets  of  methadone  5mg)    
5.1.10.  Co-‐prescription  of  naloxone  will   Project  Lazarus  reduced  80%  of  overdose  deaths  from  prescription  
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be  prescribed  for  any  of  the  following  
patient  situations:    
§   History  of  overdose  
§   SOAPP  score  >14  
§   ORT  Score  >8  
§   MME  >50mmEQ/day  

5.1.11.  Concurrent  use  of  
benzodiazepines,  sedative-‐hypnotics,  or  
barbiturates  should  generally  be  
discouraged.      
Every  effort  should  be  made  to  taper  
therapy.      
5.1.12.  Patients  with  opioid  use  disorder  
should  be  treated  using  evidence-‐based  
medication  assisted  treatment  in  
combination  with  behavioral  therapies.    
5.2.  Patients  receiving  >60  tablets  of  an  
opioid  prescription  in  a  90-‐day  period  
will  require:    
§   Office  visit  at  least  every  3  
months  with  the  prescribing  
provider  to  assess  pain  and  
function  using  a  validated  tool.  
§   Clinically  meaningful  
improvements  in  pain  and  
function  compared  to  start  of  
treatment  should  be  evident  for  
continued  prescribing.    
§   Provider  should  evaluate  the  
benefits  and  risk  of  continuing  
therapy  if  meaningful  
improvements  have  not  been  
seen  in  pain  and/or  function.    
§   If  benefits  do  not  out-‐weight  the  
risk,  the  provider  should  
consider  a  lower  dose,  taper  to  
discontinue  or  seek  alternative  
treatment  option.    
§   Validation  of  patient  risk  of  
addiction  to  prescription  opioids  
should  occur  at  least  annually  
using  a  validated  tool.    
§   Routine  urine  drug  screen  based  
on  patient  risk  category  or  
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medication  overdose  in  primary  care  sites  of  western  North  Carolina.  The  
method  used  was  to  identify  patients  at  high  risk  for  overdose  death  and  to  
provide  them  with  access  to  naloxone  education  and  a  prescription  for  the  
medication.    
  
Naloxone  Priority  Groups  and  Risk  Factors  for  Opioid  Overdose  include  
(among  others,  see  naloxone  resources):    
§   Recent  medical  care  for  opioid  overdose/intoxication/poisoning    
§   High-‐dose  opioid  prescription    
According  to  the  Lazarus  project  data,  any  patients  concurrently  using  
alcohol,  benzodiazepines,  or  anti-‐depressants  are  included  in  the  risk  factor  
group  for  overdose.    
  
Additional  factors  included:  smoking,  COPD,  lung  disease,  sleep  apnea  or  
respiratory  system  disease,  renal  or  hepatic  disease,  and  remoteness  from  or  
difficulty  accessing  medical  care.    
  
Approaching  substance  use  disorder  as  a  chronic  illness  can  help  providers  
deliver  care  that  helps  patients  stabilize,  achieve  remission  of  symptoms  and  
establish  and  maintain  recovery.    
Visit  Quantity:    
  
Regular  visits  allow  the  provider  to  assess  for  pain  and  function,  as  well  as  to  
review  risk  factors  for  misuse  or  diversion.    
  
Screening  Tools    
  
  
§   Epic  provides  the  ability  to  assess  pain  and  function  using  some  of  the  
approved  scales  for  documentation.  Validation  of  specificity  and  
validity  of  each  scale  has  been  validated  in  the  literature  and  can  be  
useful  in  discussion  and  goal  setting  with  the  patient.    
§   Discussion  around  meaningful  improvement  in  therapy  should  be  an  
ongoing  discussion  between  the  patient  and  provider.    
§   Signs  that  the  patient  may  not  be  having  meaningful  improvement  
may  be  evidenced  in  the  following:  no  attempts  to  increase  in  
physical  function,  continually  not  meeting  mutually  set  goals,  missing  
clinic  appointments,  etc.  
  
The  discussion  over  tapering  medications  and  changes  in  therapy  can  be  a  
gradual  adjustment  and  discussion  with  the  patient.  Identifying  goals  with  the  
patient  ahead  of  time  can  help  prepare  them  for  the  time  that  tapering,  or  
discontinuation  may  occur.  Identifying  with  the  patient  that  there  MUST  be  
clinically  evident  improvement  in  their  care  before  prescribing  additional  
opioids  should  occur  at  the  initial  discussion  around  goals  for  pain  and  
function.  Both  the  patient  and  provider  should  be  an  active  partner  in  
ensuring  safety  for  opioid  prescribing,  understanding  and  reducing  risk  for  
overdose  and  continued  assessment  of  needs.  
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provider  discretion  (see  
suggested  criteria).    
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Urine  drug  Screen  Risk  Categories  
  
  
  

Risk  Category  
Low  

Definition  of  Risk  
Screening  Frequency  
ORT  Score  0-‐3  
Annually  
SOAPP  0-‐7  
Medium  
ORT  Score  4-‐7  
1-‐2  times  per  year  
SOAPP  8-‐10  
High  
ORT  Score  8+  
2-‐4  times  per  year  
SOAPP  11+  
5.3.  Opioid  therapy  prescriptions  are  
Just  like  prescribing  medications  for  any  condition,  prescribing  opioid  
prescribed  as  a  trial  or  test,  where  the  
medications  should  occur  on  a  trial  basis.  Education  to  the  patient  should  
decision  to  continue  therapy  is  made  at   include  how  the  trial  will  work,  including  expectations  for  use  of  the  
a  minimum  of  every  three  months  
medications  and  goal  setting  should  occur  at  the  onset  of  the  opioid  
throughout  treatment.    
prescription.    
5.4.4.  Active  signed  controlled  substance   Controlled  substance  agreements  are  documents  that  contain  statements  to  
agreement  if  patient  received  >60  
ensure  patients  understand  their  role  and  responsibilities  regarding  their  
tablets  in  a  90-‐day  period.    
treatment,  the  conditions  under  which  their  treatment  may  be  terminated,  
  
and  the  responsibilities  of  the  health  care  provider.    
  
They  can  help  facilitate  communication  between  patients  and  the  provider.  
The  provider  should  explain  that  the  primary  reason  to  start  a  pain  contract  is  
to  keep  the  patient  safe.    
  
5.4.5.  Opioid  prescriptions  will  be  
Prescribing  more  opioid  than  necessary  can  result  in  leftover  pills,  which  are  
written  as  a  28-‐day  supply  for  ongoing  
then  available  for  diversion  and  inappropriate  use.    
opioid  therapy.  Three  consecutive  
§   Among  those  who  abuse  opioids,  over  70%  obtain  them  through  
prescriptions,  each  for  a  28-‐day  supply  
diversion  and  another  40-‐50%  obtain  them  through  family  or  friends  
may  be  prescribed.  All  three  
with  left  over  pills.    
prescriptions  must  be  dated  with  the  
§   Per  the  opioid  contract,  a  patient  is  not  to  fill  their  prescription  early  
date  the  prescriptions  are  written  (i.e.  
unless  there  is  explicit  discussion  and  validation  from  their  provider.    
no  pre-‐  or  post-‐dating)  and  may  include  
§   The  patient  should  be  notified  of  these  guidelines  and  every  attempt  
direction  to  not  fill  until  a  certain  date).    
should  be  made  to  address  any  concerns.    

5.5.  The  prescribing  provider  can  
discontinue  OR  taper  the  opioid  
prescription  if  the  patient  violates  the  
controlled  substance  agreement.  
Discontinuation  should  be  carefully  
assessed  by  the  prescribing  provider  to  
ensure  the  opioid  therapy  is  
discontinued  safely  based  on  evidence-‐
based  treatment.  Violation  of  the  

Physicians  should  be  equipped  to  deal  with  patients  who  are  found  to  be  
misusing  opioid  medications.  Possible  responses  might  include:    
§   Education  and  discussion  along  with  restatement  of  the  written  
agreement    
§   Review  of  the  written  opioid  agreement    
§   Discussion  with  others  involved  in  the  patient’s  care  
§   Change  in  the  amount  or  type  of  medication  dispensed  
§   Discussion  on  whether  the  patient  should  seek  consultation  with  pain  
and/or  addiction  specialist    
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controlled  substance  agreement  does  
not  solely  justify  a  discharge  from  the  
practice.    
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§   More  frequent  clinic  visits    
§   Instituting  regular  or  random  urine  drug  testing  for  prescription  
renewal    
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Appendix P: Screening Tools

Patient  Assessment  Tools  
The  following  tools  have  been  adopted  by  the  site  and  can  be  found  in  the  EHR  as  flowsheets.    

Pain  Enjoyment  and  General  Activity  (PEG)    

  

  

  

Opioid  Risk  Tool    
  

  

SOAPP    
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Appendix Q: Naloxone Resources from Toolkit
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Appendix R: Budget
Evidence Based Toolkit: Initial Budget
Expenses
Project Manager (RN) Donation for education
and support

$1,230.00

Data Analyst (Donation)

$216.00

Statistician (Donation)
Color Printed Educational Fliers
Binder and paper
RN education Time
Medication Assistant Education Time
Physician, NP and PA Education Time
Clinical Nurse Specialist Time
Project Mentor Time
Total:
Revenue
Project Manager Donation for education and
support
Data Analyst (Donation)
Statistician (Donation)

$122.00
$25.00
$25.00
$33.00
$130.00
$1,076.00
$49.00
$99.00
$3,005.00

Overdose death prevention

Total

$1,230.00
$216.00
$216.00
10 overdose patients in surrounding counties per
year
$1917.00 x33 (ED) = $63,261 =$632.610.
$10,000 (inpatient) x10 =$110,000 per person x 10
1,100,000.00
$1,101,662.00

Total Operating Income: $1,090,657.00.

Appendix S: Checklists and Pocket Cards from Toolkit  
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Check List for Prescribing Opioids for Primary
Care Providers Treating Adult Patients with
Chronic, non-cancer, non-palliative pain.

___ Set realistic goals for pain and function
based on diagnosis
___ Check that non-opioid therapies have
been tried and optimized
___ Discuss risk and benefits with Start
Talking document concepts. Even if the patient
is not a new opioid user, the discussion should
still occur.
___ Initiate opioid use contract or start talking
as needed.
___ Elevate risk of harm or misuse, including
risk factors of overdose
___ Risk factors with the patient

Centers for Disease Control Evidence

§   Benefits of long-term opioid therapy
for chronic pain is not well supported
by the evidence
§   Short-term benefits are small to
moderate for pain but inconsistent for
function.
§   Insufficient evidence for long-term
benefits in lower back pain, headache
and fibromyalgia.
Non-Opioid therapies

*To be used alone or in combination with
opioids, as indicated.
§  
§  
§  
§  

NSAIDs, TCAs, SNRIs, anti-convulsants
Physical therapy, exercise, weight loss
CBT behavioral treatments
Procedures such as intra-articular
injections

___ Check PMPD data
___ Check urine drug screen
___ Set criteria for trial of medication and
reassessment goals (1-4 weeks)
___ Assess baseline pain and function using
scale (i.e. PEG)
___ Prescribe at lowest possible dose for
shortest duration.
  

  

  

Risk Factors for Misuse
§   Illegal drug use including
prescription drug use for
nonmedical reasons
§   History of SUD or overdose
§   Mental health conditions
§   Sleep disordered breathing
§   Concurrent benzodiazepine
use.
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Tips for Re-Assessment During Return Visit

___ Assess pain and function using same scale as previous. Compare to baseline.
___ Evaluate for harm or misuse:
§   Over-sedation: consider tapering dose
§   PDMP data
§   Discuss use of medications and assess for aberrant behaviors
___  Check  that  non-‐opioid  therapies  have  been  optimized    
___  Calculate  opioid  dosage  morphine  milligram  equivalent  (MME)    
§   If  >  50MME/day  total,  increase  frequency  of  follow  up  and  consider  adding  naloxone  
as  a  co-‐prescription  
§   If  >90MME/day  total,  co-‐prescribe  naloxone  and  justification  is  necessary  along  with  
consideration  of  specialist  referral.    
___  Determine  next  steps:  continue,  adjust,  taper  or  stop  opioids    
___  Schedule  regular  reassessment  intervals  (<3months)    
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Appendix T: Gender Frequencies for Data Collection
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Appendix U: Short Acting Opioid Frequencies
Group=Pre-Implementation
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Appendix V: Long Acting Opioid Frequencies
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Appendix W: Benzodiazepine Presence Frequencies
Group=Pre-Implementation
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Appendix X: Benzodiazepine Pre-and Post-Comparisons
Comparing Benz Pre to Post
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Appendix Y: Morphine Mill- Equivalence Pre-and Post-Distributions

Distribution of MMEQ
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Appendix Y: Urine Drug Screen Frequencies
Group=Pre-Implementation
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Appendix Z: Urine Drug Screen Pre- and Post Implementation Comparisons

Comparing UDS Pre to Post
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Appendix AA: Medication Contract Frequencies
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Appendix BB: Medication Contract Pre- and Post Implementation Comparisons
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Appendix CC: Michigan Start Talking Form Frequencies
Group=Pre-Implementation
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Appendix DD: Michigan Start Talking Form Pre-and Post-Implementation Comparisons
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Appendix EE: Provider Survey

  

  

  

  

Evidence-based    
Toolkit  for  Reduction    
of  Overdose  Risk  in    
Primary  Care Patients    
on Opioid
Therapy
Katelin Aris
DNP Project Proposal Defense
April 1, 2019

Acknowledgements
Primary Mentor: Dr. Tricia Thomas
Secondary Reader: Dr. Karen Burritt
Site Mentor: Dr. Caroline Ring

Objectives  for Presentation
1. Introduce the background information and
prevalence of opioid prescribing and overdose
deaths in the state of Michigan.
2. Identify and examine the clinical problem.
3. Outline the quality improvement initiative
and implementation plan that took place.
4. Discuss results and limitations.
5. Outline dissemination plan, sustainability and
reflect on DNP essentials.

Introduction
• More than 7.8 million patients received over
103 million opioid prescriptions over the
course of a 5-year review in Michigan
• Resulted in over 5,000 opioid overdose deaths.
• Increased availability of prescription drugs,
along with misconceptions around safety of
prescribed medications has led to growth of
prescription drug users and mis-users.

Introduction
• Michigan is one of the highest ranked states in the
nation for prescribing of opioid pain relievers.
• Almost 60% of opioid overdose deaths had a
prescription filled for hydrocodone within the last
30 days.
• There has been a 100% increase in opioid deaths
from 2010-2016 and Michigan is ranked 7th in the
nation.

Introduction
1st Narcotic Prescription
v
v
v
v

Primary Care: 42.9%
Surgery: 15.8%
ED/Urgent Care: 14.3%
Dentistry: 16.1%

v Average age: 45.7 years
v 10.9% of patients had a narcotic
prescription before the age of 20.
v Among patients whose first  narcotic
was written between 2014-2015, those
who died of overdose death were
prescribed narcotics only 8 months
prior to death.

Michigan Prescription Drug & Opioid Abuse TaskForce.
(2015).

Assessment of the Organization

Framework:  Burke  & Litwin
Figure 1. A model of organizational performance and change. Re-created from “A Casual Model of Organizational Performance and
Change,” by W. W. Burke and G. H Litwin, 1992, Journal of Management, 18, 528. Copyright 1992 by Southern Management Association
External
Environment

Leadership
Organizational    
Culture

Mission and    
Strategy
Management    
Practices
Structure

Systems  (Policies    
and Procedures)

Work  Unit Climate

Task  and    
individual skills

Motivation

Individual and
Organizational Performance

Individual Needs    
and Values

IRB Approval

Stakeholders
•
•
•
•
•
•
•
•

Prescribers
Medical Assistants
Registered Nurses
Leadership teams at the sites
Opioid Steering Committee
Pain Management physician leads
Additional mentors (CNS)
Patients

SWOT
Strengths
•
•
•
•
•
•

Engaged Leadership including supervisor, manager,
director
Low provider and staff turnover
Consistent Medical assistant/prescriber relationship
Consistent providers in the practice
Process improvement in place
DNP prepared NP

Opportunities
•
•
•
•
•
•

Consumer demographics
Recent state policy changes
Organizational policy changes coming
Increase quality of care with evidence based care
solutions
Part of a larger health care organization
Reduce risk of overdose

Weaknesses
•
•
•
•
•

•
•
•
•
•
•

High panel load for each provider
Patients on long term opioid regimens
No current EHR notification for high mmEQ
Many screening tools already in place
Recent EHR change with large focus on recent big
changes.

Threats
Patient satisfaction regarding pain management regimens
and their satisfaction with pain control.
Patients unaccepting of changes in long term regimens.
Limitations in health literacy in the community
Limited transportation
High no show rate at the office
Staff and provider buy in to practice change.

Clinical  Practice Question
• Does implementation of an opioid prescribing
evidence-based toolkit increase provider
confidence in prescribing best practice and
increase adherence to organizational policy?

Literature Review

Aim  of  Literature Review
Goal: Synthesize opioid prescribing best practice literature to generate a
toolkit with targeted guidelines for implementation in primary care.
Questions to address:
• Does implementation of evidence-based opioid guidelines impact
patient outcomes, including reduction of total morphine milequivalents, reduction in risk for overdose, and co-prescription of
naloxone?
• Does implementation of opioid guidelines increase provider awareness
to best practice with regard to opioid prescribing?
• Do evidence-based opioid guidelines for chronic pain reduce risk of
abuse/addiction for patients treated by primary care providers,
including adherence to office policies and protocols?
• What are the most effective methods for implementation of evidence
based tools and guidelines in primary care?

Review Method
• Preferred Reporting Items for Systematic Reviews and
Meta-Analysis (PRISMA) method.
• CINAHL and PubMed Databases.
• 2008-2018.
• Studies examined pertaining to physicians in primary
care and was centered around opioid prescribing and
excluded other pain management strategies.
• Palliative care, cancer and pediatrics/neonatal excluded.
• Keywords: opioid, opioid guidelines, risk reduction and
primary care.

PRISMA Figure

Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and
Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

Summary  of  Table  and Results
• Gaiennie and Dols (2018)
• Quality Intervention

• Liebschutz et al. (2017).
• RCT

• McCracken et al. (2012)
• RCT

• Quanbeck et al. (2018)
• RCT

• Tournebize et al. (2016)
• Systematic Review

• Von Korff et al. (2016).
• Quasi-experimental design

Evidence  for Project
• 3 RCT, 1 systematic review, 1 quasi-experimental, 1 quality
improvement intervention.
• Sources reported the outcome measures as improvement in
provider knowledge and adherence to guidelines.
– Increased adherence to urine drug testing, use of treatment
agreements, and opioid-benzodiazepine co-prescribing rates.
– Increase in provider intention to use tools and well-being.
– Reductions in total opioid prescriptions and reduction in total
morphine mill-equivalents.
– Increase in pain management referrals.
– Overall increases in quality of care and safety.

Conceptual Models and
Frameworks

Model  to  Examine Phenomenon

Levenson, J. (2017). Behavioral health: moving to a chronic caremodel
helps payers, providers and patients. MAP Health Management.

Implementation Model

Kotter’s 8 Step
Model for Change

Kotter, J. (1996). 8 Step Process for changemanagement.

Project Plan
and Implementation

Project  Purpose  & Objectives
• Goal: Assist primary care providers in their care of
patients who are on opioid therapies.
• Objectives are to address:

– Provider comfort level with opioid prescribing, policy and
guidelines.
– Adherence to MI opioid laws and organizational policy,
including use of medication contract, opioid start talking
document and urine drug screen.
– Identification of and reduction in total morphine mmEQ.
– Rates of co-prescribing for benzodiazepines and opioids.
– Co-prescription of naloxone

Design,  Setting  and Participants
• Design: The design for this evidence-based
initiative was a quality improvement project and
translation of evidence into practice.
• Setting: 2 northern Michigan primary care offices.
– 8 total prescribers (3 Physicians, 3 PA, 2 NP).
– 28,000 annual patient visits

• Primary staff included: Prescribers, RNs, Medical
Assistants.

Implementation  Strategy  & Element
Steps for Implementation using Theory

1). Create urgency
-Literature review and organizational assessment
-Present this topic across various forums
2). Build a coalition:
-Meeting with medical director
-Attend clinical practice steering meetings
-Cultivate relationships with staff
3). Create a vision for change with creation of the toolkit, using
the following as a guide:
-Evidence based guidelines
-Site Leadership
-Organizational policy

Implementation  Strategy  & Element
Steps for Implementation using Theory

4)

Communication of the vision through education
and information around toolkit to all involved:
-Presentations
-Emails
-1:1 Face to face discussion

5) Empower action: go live with the evidence-based toolkit.
-Provide at the elbow support, as needed.
-Identify and target toolkit changes/updates as
needed.

Implementation  Strategy  & Element
Steps for Implementation
6) Create quick wins:
-Create and embed a best practice advisory into the
electronic health record to aid the providers in their daily
work (i.e. naloxone co-prescription suggestion and ease of
ordering ).
7) Build on the change:
-Weekly feedback to providers and staff.
-Weekly discussion of key points and reinforcement of
concepts.
8) Make it stick:
-Deliver final report to leadership and present
sustainability plan.

Implementation  Strategy  & Element
Toolkit contents:
• Organizational guideline.
• CDC guidelines for opioid prescribing in primary care.
• Patient education materials through the CDC
• Harm Reduction Coalition and the Lazarus Project information.
• UptoDate
• Screening tools and methods.
Primary delivery methods:
• Handbook format.
• Checklists.
• Updates

Evaluation  & Measures
• Evaluation through retrospective data review occurred
following IRB approval at the site and through GVSU
• Additional primary measures:
– Observation through site shadowing during clinical
rotations
– Discussion with clinicians
– Pre and post survey for prescribers

Sample  Survey  for  Primary  Care    
Prescribers
Please rate the following on a scale of 1 to 5.
1 = strongly disagree

2 = disagree

3 = neutral

4 = agree

5 = strongly agree

Comfort Level
• I feel confident in understanding the legislative changes in the state of Michigan
with regard to opioid prescribing.
• I feel confident in understanding the organization’s policies for opioid prescribing.
• I find it easy to know how many morphine mill equivalents for my patients who are
prescribed opioids.
• I think patients could use more education with regard to opioid prescribing changes.
Awareness/Practice
• Most of my patients on opioids have signed opioid prescribing contracts.
• Most of my patients on opioids have at least one UDS per year.
• Most of my patients on opioids are under a daily limit of 50 mmEQ.

Data Review
Data Variables for Pre- and Post Implementation Evaluation
•
•
•
•
•
•
•
•
•
•
•
•
•

Age
Gender
Previous diagnoses of opioid overdose
Current diagnosis of opioid overdose
Short acting opioid name, dose, and strength
Long acting opioid name, dose and strength
Benzodiazepine presence or absence
Screening tool presence or absence (PEG, SOAPP, ORT)
Morphine mill equivalents (calculated by me)
Urine drug screen presence or absence
Medication contract presence or absence
Start talking document presence or absence
Provider pre- and post comfort level with guidelines.

Analysis Plan
• Report out of the EHR from the site data analyst
• Placed on a password driven, secure m: drive
• The DNP student was the primary source of data collection; all
data points were then collected from the EHR following
guidelines put forward by the site for data security.
• De-identified prior to transfer to Statistician
• The GVSU Statistician assisted in review and analysis of data
and appropriate statistical method for evaluation.

Analysis Plan
•

•

Analysis of data pre-implementation:
– Data is exploratory data and helped for foundation for implementation
of the toolkit.
– Calendar year 2018 selected
– Site A: Small n, reviewed all possible patients without duplicates
(n=22).
– Site B: Large n, reviewed every 10th chart, removing cancer pain
(n=39).
Analysis of data post-implementation:
– Obtained at one month post implementation
– Both sites small n = need to review every chart without duplicates (Site
A = 6, Site B = 14)
– Data determined effectiveness of interventions.
– Data determined next steps for dissemination, adjustment of toolkit
contents, further education needs and sustainability.

Timeline
April-May 2018:
• Advisory team formation and DNP project identification
June 2018
• Prospectus Written
July-August 2018
• Organizational Assessment and Literature review
September-October 2018
• IRB Application and Determination
November 2018
• Proposal Defense
December 2018
• Creation of toolkit
• Prescriber level setting focus group
January/February 2019
• Staff education through emails and face to face communications
• Implementation of toolkit and support
• BPA change request in EHR
March 2019
• Auditing and feedback, Analysis of data post-implementation, recommend changes
April 2019
• Final presentation to leadership, sustainability, project defense, and submission to
Scholar Works.

Results and Sustainability

Prior  State Practices
• Combined Site Data
– Total Prescriptions: 427
– Total N reviewed: 61
– 27 Male Patients
– 34 Female Patients

Prior  State Practices
Site A
• Total prescriptions written: 48
• Total N reviewed: 22
• 12 Male Patients
• 10 Female Patients
• No patients with short and long acting
prescribed.

Prior  State Practices
Site B
• Total prescriptions written: 379
• Total N reviewed: 39
• 15 Male patients
• 24 Female Patients
• 6 patients on both long and short acting
opioids

Short  Acting Medications
Combined Data
Group=Pre-Implementation

Group=Post-Implementation
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Long  Acting  Medications Combined
Data
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Measures
• Morphine mmEQ
– Both sites:
• Pre: Total Daily mmEQ: 61.4
• Post: Total Daily mmEQ: 35

– Site A Pre/Post Implementation

Goal: Reduction of
mmEQ overall
Reduction of 26.4
mmEQ/day

• Pre: Total Daily mmEQ: 17
– One patient >50mmEQ

• Post: Total Daily mmEQ: 25
– One patient >50mmeQ

Increase of 8
mmEQ/day

– Site B Pre/Post Implementation
• Pre: Total Daily mmEQ: 85
– 14 patients >50 mmEQ

• Post: Total Daily mmEQ: 39
– 2 patients >50mmEQ

Reduction of 46
mmEQ/day

Morphine  Milliequivalents  
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Measures
Morphine mmEQ
• There is not sufficient evidence to say that the
distribution of morphine milliequivalents
differs pre and post implementation.
• Wilcoxon Rank Sum test (S = 7.575, p=0.495)

Measures
• Co-prescribed benzodiazepine
– Both sites:
• Pre: 17/61 present (28%)
• Post: 2/20 present (1%)

Goal: Reduction of coprescribed
benzodiazepines
Reduction of 18%

– Site A Pre/Post Implementation
• Pre: 3/22 present (14%)
• Post: 1/6 present (17%)

– Site B Pre/Post Implementation
• Pre: 14/39 present (36%)
• Post: 1/14 present (7%)

Increase of 3%

Reduction of 29%

Benzodiazepine Comparisons
Comparing  Benz  Pre  to Post
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Measures
Co-prescribed benzodiazepine
• There is not sufficient evidence to say that
proportion of patients that had benzos differs
pre and post implementation
• Fisher’s Exact Test (p = 0.1339)

Measures
• Urine Drug Screen
– Both sites:
• Pre: 37/61 present (61%)
• Post: 10/20 present (50%)

Goal: Increase % of
patients with a UDS

Reduction of 11%

– Site A Pre/Post Implementation
• Pre: 12/22 present (55%)
• Post: 5/6 present (83%)

Increase of 28%

– Site B Pre/Post Implementation
• Pre: 25/39 present (64%)
• Post: 5/14 present (36%)

Reduction of 28%

Urine  Drug  Screen Comparisons
Comparing  UDS  Pre  to Post
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Measures
Urine Drug Screen
• There is not sufficient evidence to say that
proportion of patients that got a drug screen
differs pre and post implementation
• Chi Square test, x2=0.2, p = 0.6551)

Measures
• Medication Contract
– Both sites:
• Pre: 41/61 present (67%)
• Post: 18/20 present (90%)

Goal: Increase % of
patients with a Med
Contract
Increase of 23%

– Site A Pre/Post Implementation
• Pre: 20/22 present (91%)
• Post: 6/6 present (100%)

Increase of 9%

– Site B Pre/Post Implementation
• Pre: 21/39 present (54%)
• Post: 12/14 present (86%)

Increase of 32%

Medication Contract
Comparing  MedCon  Pre  to Post
40
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Measures
Medication Contract
• There is sufficient evidence to say that
proportion of patients that had a medical
contract differs pre- and post implementation.
• Chi-square test, x2=3.95, p=0.0468.
• 90% post versus 67% pre implementation

Measures
Michigan Start Talking Document
– Both sites:
• Pre: 5/61 present (8.2%)
• Post: 8/20 present (40%)

Goal: Increase % of
patients with a Start
Talking Document
Increase of 31.8%

– Site A Pre/Post Implementation
• Pre: 3/22 present (14%)
• Post: 2/6 present (33%)

– Site B Pre/Post Implementation
• Pre: 2/39 present (5%)
• Post: 6/14 present (43%)

Increase of 19%

Increase of 38%

Michigan  Start  Talking Frequencies
Comparing  StartTalk  Pre  to Post
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Measures
Michigan Opioid Start Talking Document
• There is sufficient evidence to say that
proportion of patients that had a document
differs pre and post implementation
• Fisher’s exact test, p = 0.0022.
• 40% post versus 8.2% pre implementation

Measures
Naloxone Co-prescription and Screening Tools
• Both sites had no instances pre- or post
implementation of naloxone co-prescription or
use of screening tools.

Provider Characteristics
• N= 4
• Completion: 75% (3/4 responses)
• Pre-implementation:
– Highest ranking: Awareness questions
– Lowest ranking: Confidence questions

• Post-implementation:
– Highest ranking: Confidence questions
– Lowest ranking: Awareness questions

Discussion
• mmEQ:
– Higher mmEQ associated with higher overdose risk
– 50mmEQ is CDC gold standard for prescribing
– Site A: generally safe profile for prescribing in association
with mmEQ
• Increase in post-implementation phase due to small N

– Site B: room for improvement which was gained with
toolkit.
• 46% reduction in mmEQ
• Not statistically significant but is clinically significant

– Formulation of opioids (LA/ER vs. SA)
• Site B: Complete reduction in dual formulation

Discussion
• Co-prescribed benzodiazepine
– Concurrent use is associated with higher overdose risk
– Site A: generally safe profile for prescribing in
association co-prescribed benzos
• Increase in post-implementation phase due to small N

– Site B: room for improvement which was gained with
toolkit.
• 29% reduction in patients on co-prescribed benzos
• Not statistically significant but clinically significant

Discussion
• Urine Drug Screen
– Helps assess overdose risk due to additional
substances on board
– Site B: reduction in adherence; may be due to
decreased mmEQ and co-prescribed benzos

• Start Talking Document and Medication Contracts
– Increases patient’s understanding of risks of opioids
– Came into practice June 2018
– Both statistically significant change from adherence
pre and post intervention

Discussion
• Screening Tools
– Screening tools for assistance in opioid prescribing of mixed
results in literature.
– Organizational policy guides providers to assess overall pain
management goals and function, thus use of screening tools are
necessary.

• Naloxone
– Risk mitigation with naloxone has not been studied in primary
care but is successful in community based interventions.
– Post implementation, fewer patients met this need as described
by the CDC.
Additional interventions and education needed to promote
adherence.

Discussion
• Provider Comfort Level
– Lack of confidence in prescribing opioids known in
the literature
– Per CDC, most providers not consistent with practices
to decrease risk for mis-use/overdose
– Post: Increase in provider comfort characteristics and
decrease in provider awareness (EHR is a factor)
– Again, not statistically significant but clinically
relevant
• Guides efforts needed to address practice gaps.

Limitations
•
•
•
•

Electronic Health Record
mmEQ/day tabulation
Michigan Start Talking Legislation
Missing Data
– Prescriber and patient characteristics
– Lack of qualitative approach
– No consideration of indication, duration, co-morbidities, mental health, age, etc.

•
•
•
•
•

Sample weaning plans not included, alternative pain management modalities and
referrals not included.
Data review timeframe
Survey
Short implementation period and small sample sizes
Pain management physician

Implications  for Practice
•
•
•
•

Evidence-based approach to changing practice
Patient centered approach to care
Ensuring understanding of risk
Ease of use of electronic health record for
viewing.
– BPArequest

• Consider the “person” behind the numbers.

Next Steps

• Completion of Naloxone BPA and patient education
materials.
• Continued emphasis on prescriber/patient relationship and
MA conversations/scripting.
• Implementation of additional Opioid tools in EHR
(dashboard).
• Initiation of work on electronic care-set for withdrawal.
• Support of prescriber algorithms
• Weaning
• Opioid Use Disorder Treatment
• Alternative Pain Strategies with medication and nonpharmacological solutions
• Referral to pain management or alternative professionals

Resources  & Budget
Evidence Based Toolkit: Initial Budget
Expenses
Project Manager (RN) Donation for education and support

$1,230.00

Data Analyst (Donation)

$216.00

Statistician (Donation)
Color Printed Educational Fliers
Binder and paper
RN education Time
Medication Assistant Education Time
Physician, NP and PA Education Time (including focus groups)

$122.00
$25.00
$25.00
$33.00
$130.00

Clinical Nurse Specialist Time
Project Mentor Time
Total:
Revenue
Project Manager Donation for education and support
Data Analyst (Donation)
Statistician (Donation)

Overdose death prevention

$1,076.00
$49.00
$99.00
$3,005.00
$1,230.00
$216.00
$216.00
10 overdose patients in surrounding counties (Mecosta, Osceola and Lake) per year
$1917.00 x 33 (ED) = $63,261 =$632.610.
$10,000 (inpatient)x10 =$110,000 per person x 10
1,100,000.00
Source: Mack (2018)

Total

$1,101,662.00

Sustainability Plan
• Feedback provided during implementation phase of project.
• Provide final presentation of overall work completed and
outcomes with leadership team.
• Share barriers and successes.
• Give best practice recommendations and lessons learned
following implementation.
• Provide feedback and recommendations for continuation
and/or alteration of best practice advisory within the
organization based on implementation.
• Prepare for implementation of this project system wide.
• Provide recommendations for updating of organizational
policy, checklists and implementation tools with legislative
changes upcoming in 2019.

Dissemination
•
•
•
•
•

Local newspaper and 9&10 News
The Crisis Next Door Presentation
1:1 Feedback to Prescribers
Local Leadership and provider meetings
Opioid Steering Committee and leadership
committees as requested
• Poster Presentation

DNP  Essentials Reflection
• The Grand Rapids Red Project
• Naloxone education to Emergency Department staff
• Overdose Prevention Training: inpatient and outpatient
based rehabilitation units and 1:1 counseling.
• Needle and Medication Takeback Days
• Ethics Shadow and various ethics education offerings
• Opioid Education and Buprenorphine Certificate
• Policy and Advocacy
• AANP Conference
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